CA2284653C - Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy - Google Patents

Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy Download PDF

Info

Publication number
CA2284653C
CA2284653C CA002284653A CA2284653A CA2284653C CA 2284653 C CA2284653 C CA 2284653C CA 002284653 A CA002284653 A CA 002284653A CA 2284653 A CA2284653 A CA 2284653A CA 2284653 C CA2284653 C CA 2284653C
Authority
CA
Canada
Prior art keywords
hydrogen
independently selected
nitrogen
acid
hydroxyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002284653A
Other languages
French (fr)
Other versions
CA2284653A1 (en
Inventor
Sudhakar Kasina
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Publication of CA2284653A1 publication Critical patent/CA2284653A1/en
Application granted granted Critical
Publication of CA2284653C publication Critical patent/CA2284653C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00Compounds containing elements of Groups 7 or 17 of the Periodic System
    • C07F13/005Compounds without a metal-carbon linkage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/087Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being an annexin, e.g. annexin V
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/34Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a mercapto group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D257/00Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/10Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/321,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Abstract

The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds. Another aspect of the invention provides for the use of the chelation compounds described above in methods for diagnostic and therapeutic purposes. A diagnostic method is described for detecting the presence or absence of a target site within a mammalian host. This method comprises providing to cells a diagnostically effective dose of a compound of the present invention which contains a metal radionuclide, such as 99mTc and/or 111In, and detecting the biodistribution of the radionuclide. A therapeutic method is described for delivering a radionuclide, such as 186Re/188Re, 90Y, and 153Sm, to a target site within a mammalian host. This method comprises providing to cells a therapeutically effective dose of a chelate compound of the present invention.

Description

C~CA 02284653 2008-04-18 TETRAAZA-OR N2S2-COMPLEXANTS, AND THEIR USE IN RADIODIAGNOSTICS OR
RADIOTHERAPY
= Technical Fiel..
The present invention relates generally to chelation compounds, radionuclide metal chelate compounds (i.e., complexes) and radiolabeled targeting moieties (i.e., conjugates) formed therefrom, and methods of making and using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to compounds in which at least two of the chelating atoms are nit-rogen atoms which are directly attached to aromatic rings and there is a non-hydrogen substituent d=rectly attached to at least one of these nitrogen chelating atoms.

Background of the Inventiop Radiolabeled chelation compounds have been studied and used as pharmaceuticals for diagnostic and therapeutic purposes for a number of years. The requirements for a useful radiolabeled chelating compound are well known to those skilled in the art of nuclear medicine and radiopharmaceutical research. Briefly, these requirements include: efficient final preparation of the radiopharmaceutical, such that preparation in the hospital or pharmacy is possible; e:ficient transport of the radiopharmaceutical to the target organ;
efficient extraction of the radiopharmaceutical by the target .30 organ, such that adequate target to background ratios are achieved to allow diagnostic and therapeutic distinctions; and adequate retention in the target organ to allow detection and therapy using conventionally available radiation monitoring equipment. Representative organs of interest are those containing malignant cells or activated platelets. Imaging agents and therapeutic agents have typically been unsuitable WO 98/43678 PCT/US98/05858_ due to poor in vivo stability post-chelation, resulting. in inadequate retention and accretion by the effected cells.._.
_ _ _., ... . . _ . .... _. . .___ . .. .. _ _ Thus, there is a need in the art for improved chelation compounds for imaging and therapy. The present invention fulfills this need and further provides other related advantages.

Summarv of the Invention Briefly stated, the present invention in one aspect provides compounds having the formula:

R \rC n R7 lY N N

'='' R4~X A X' Rs wherein: -n = 0 or 1;
R1 and R2 are independently selected from hydrogen, =0, with the proviso that both are not =0, -(CH2).-Z where m is 0-10 and Z represents a conjugation group or targeting moiety, and -(CHZ)m-w where m is 0-10 and W represents a hydrolyzable group, or Ri and R, are taken .. together to form a cyclic anhydride or a _ benzene ring;
R3 is hydrogen, lower alkvl, alkoxy, halogen, hydroxyl, nitro, - (CHZ);,-Z or - (CH2),-W;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower.alkyl, alkoxy, halogen, hydroxyl, nitro, - (CHZ) ,-Z and - (CHZ) ,-W;
R. and are independently selected from hydrogen with the proviso that both are nct hydrogen, lower alkyl, a.ikoxy, halogen, hydroxyl, n=tro, - (CHz) õ-W and R:2 , where Q
-(CH,)P ''-Q

represents a multivalent acid functionality group able to coordinate with metal ions, and p = 0 to 1; R12 and R13 are independently selected from hydrogen, hydroxyl, carboxy_, phosphonic and hydrocarbon radicals having from 1-10 carbon atoms, and physiolog:cally acceptable salts of the acid rad=cals;
X, X', Y and Y' are independently selected from carbon, nitrogen, oxygen and sulfur tc independently form five or six member aromatic rings wherein the remainina ring atoms are carbon;
A and A' are independently selected from sulfur, nitrogen and oxygen, where sulfur may bear a hydrogen or a sul=ur protecting group, or where A and A' are both sulfur, A and A' may be joined 2C together by a bond; where an oxygen or a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear Re or R1, or both and A' may bear R 9 or R1; or both, wherein R9, R9, R;,~
and R;_ are independently selected f:orr, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH,).,-Z, -(CHz) -W and _ ; or R. and - (CH') p C-Q
~:3 Rlo mav be joined to form a cyclic anhydride or R9 and R,, may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R,o and R11 may be joined to form T, where T
is CH (CH) n CH and n is 0 to 1, / I I \ R
R 2~ 1 R , and R,' and R2' are independently selected from hydrogen, =0, with the proviso that both are not =0, -(CHZ),-Z and -(CHZ),n-W or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R,' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2'),-Z and -(CH2),-W; and said compound has at least one Z, W and Q.
In another aspect, the invention provides chelates ccmprising radionuclide metals (including oxides or nitrides thereof) complexed by a compound described above. A preferred metal chelate compound is of the formula:

Rl i 3 /R~
C._ R6 ~ ~ ~R7 =
Y N ,N
R/X A, X' Rs wherein: M is a radionuclide metal or an oxide or a nitride thereof selected from technetium, copper, rhenium, samarian, yt:rium, indium, lead, bismuth, ruthenium, rhodium, gold and palladium;
n = 0 or 1;

R1 and R. are independently selected from hydrogen, =0 with the proviso that both are not =C, -(CH2),-Z where m is 0-10 and Z renresents a conjugation group or targeting moiety, and 5 -(CHz),n-W where m is 0-10 and W represents a hydrolyzable group, or R1 and R, are taken together to form a cyclic anhydride or a benzene ring;
R3 is hydrogen, lower alkyl, alkoxy, ha'-ogen, hydroxyl, nitro, -(CHZ) m-Z or -(CHz) õ-W;
R4 and R5 are attached at one or mcre of the ring positions and are independent-'_y se-ected from hydrogen, lower alkfl, a-'koxy, halogen, hydroxyl, nitro, and R6 and R, are independently selec-:ed from hydrogen with the proviso that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CHZ) .-Z, -(CH 2) rt,-W- and where Q
(CH')P-C-Q

represents a multivalent acid functionality group able to coordinate with metal ions, and p = 0 to 1; R12 and Rlj are independently selected from hydrogen, hydroxyl, carboxyl, phosphonic and hydrocarbon radicals having from 1-10 carbon atoms, and physiologica'6ly acceptable salts of the acid radicals;
X, X', Y and Y' are independently selected from carbon, nitrogen, oxygen and sulfur to independently form 5 or 6 member aromatic.rings wherein the remaining ring atoms are carbon;
A and A' are independently selected *rom sulfur, nitrogen and oxygen, where A or A' is nitrogen, A may bear R9 or R,o or both and A' mav bear R9 or R. or both, wherein Rõ R9, R:, and R. are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, - (CH,),n-Z, -(CH,) ~-W and R12 ; or R9 and R10 may be - (CH2)P C-Q
Ri3 joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R: and R1I may be joined to form T, where T is CH (CH) n CH and n is 0 to 1, I \
R, R2 R
3' and R1' and R,' are independently selected from hydrogen, =0, with the proviso that both are not =0, -(CH2)R,-Z or R:' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CHZ) ,,,-Z or - ( CHz ) .,-W; and said compound has at least one Z, W or Q.
Yet another aspect of the invention provides for the use of the chelation compounds described above in methods for diagnostic and therapeutic purposes. A diagnostic method is described for detecting the presence or absence of a target site within a mammalian host. This method comprises providing to cells a diagnostically effective dose of a comDound of the present invention which contains a metal radionuclide, such as 99mTc and/or 1='in, and detecting the biodistribution of the radionuclide. A therapeutic method is described for delivering a radionuclide, such as le6Re/=aaRe, 30Y, and i53Sm, to a target site within a mammalian host. This method comprises providing to cells a therapeutically effective dose oT a chelate compound of the present invention.
Other aspects of the invention will become evident upon reference to the following detailed description.
Detailed Descr;iption of the Invention Prior to setting forth the invention, it may be helpful to an understanding thereof to set forth definitions of certain terms to be used hereinafter.
TarcLeting moiety - is any molecule that binds to a defined population of cells, and includes analogs of naturally occurring and synthetically or recombinantly prepared molecules. The targeting moiety may bind a receptor, an oligonucleotide, an enzymatic substrate, an antigenic determinant, or other binding site present on or in the target cell population. For example, a protein may be a tazgeting moiety. Antibcdies and peptides are used throughout the specification as prototypical examples of targeting moie--ies.
Tumor is used as a prototypical example of a target in describing the present invention.
Protein - as used herein, includes proteins, fusion proteins, polypeptides and peptides; and may be an intact molecule, a fragment thereof, or a functional equivalent thereof; and may be genetically engineered.
Antibodv - as used herein, includes both polyclonal and monoclonal antibodies; and may be an intact molecule, a fragment thereof, or a functional equivalent thereof; and may be genetically engineered; examples of antibody fragments include F(ab')2, Fab', Fab and Fv.
The present invention provides chelation compounds and = radionuclide metal chelate compounds (i.e., complexes) prepared therefrom, as well as radiolabeled targeting moieties having the chelation compounds or chelates attached thereto (i.e., conjugates). The radionuclide metal chelates of the present invention may be attached to targeting moieties, such as antibodies and proteins, to form radiolabeled targeting moieties having diagnostic and therapeutic use.
Alternatively, the radionuclide metal chelates of the present invention may be used for diagnostic and therapeutic purposes without attachment to targeting moieties.
The present invention provides compounds that have a variety of uses, including for malignant cell imaging and therapy as well as thrombus imaging. The compounds are capable of rapidly complexing a metal as well as forming a stable metal chelate (complex) . The presence of nitrogen atoms within the chelating compound accelerates complex formation with the metal. This acceleration is due in part to the fact that a metal (e.g., technetium) is a soft acid, and nitrogen (in the form of an amine or amide) is a base. Amines generally provide for a greater increase in che'-atior, ra,:es than amides. Where sulfur atoms are additicnal1-y present within the chelating compound, they also provide for an increased rate of metal complexation and contribute to the stability of the resulting chelate. The presence of phenolic hydroxyl groups within the chelating compound aid in faster kinetics of metal ion chelation. The compounds of the present invention are characterized by desirable metal complex formation kinetic properties and desirable metal-chelate retention thermodynamic properties. The compounds of the present invention have the further advantage of nitrogen atoms attached directly to aromatic rings which aid in fast kinetics of chelation and further enhances the stability of the aromatic esters of this invention with respect to hydrolysis in the bloodstream. Furthermore, an additional advantage of the present invention is the presence of substituents attached to the nitrogen atoms within the chelating compound, which imparts a higher basicity to the chelation compound and allows for additional donor atoms for complexation, thereby expanding the type of radionuclides useful for radiotherapy and radiodetection in the present invention. In addition to the above advantages, the presence of substituents enhances pharmakokinetics and pharmacodynamics, such as the biopharmaceutical properties (i.e., absorption, distribution, metabolism and excretion).
The chelation compounds of the present invention have the following formula (I):

R \'\FC"n R, Y N N Y'~
R4 x A X' R5 Examples of specific embodiments of the elements o'_ the above formula include the following.
R; and R2 may be independently selected from hydrogen (H) ;
an oxy group (=0); -(C:i2),-Z where m is 0-10 and Z represents a conjugation group or targeting moiety; or -(CHz)T-W where m is 0-10 and W represents a hydrolyzable group. As used herein, the phrase independent'_y selected means the selection of one substituent may be made without regard for the selection of any other substituent. Alternatively, R. and R~
may be taken together to form a cyc:ic group, such as an anhydride or a benzene ring. As used herein, a benzene ring may be ber.zene or benzene with cne or more substituents. A
substituent may be any electron donating (methyl, methoxy, amino and the like) and/or eleztron withdrawing (halogens, nitro, carboxy, nitrile and the like) and functional groups (esters, imidates, carbaminates and the like) known in the art. Examples of such substituents include Cl, CH31 OC::3, F, Br, I, CF3 and a triazene, such a -N=N-N(CH3) 2.
As noted above, Z represents a conjugation group or a targeting moiety. A "conjugation group" in the compounds of the present invention is any chemically reactive group capable of forming a covalent bond with a targeting moiety under conditions that do not adversely affect the targeting moiety's functional properties. For example, where the targeting moiety is a protein such as an antibody, the conjugation group is sufficiently reactive with a functional group on the protein so that the reaction can be conducted in substantially aqueous solutions and does not have to be forced (e.g., by heating to high temperatures which may denature the protein).
A conjugation group may be strongly electrophilic or nucleophilic and thereby capable of reacting directly with a targeting moiety. A precursor to a conjugation group may be a weaker electrophile or nucleophile that requires activation prior to conjugation with a targeting moiety. Conversion of a group from a precursor group to a conjugaticn group is generally performed in a separate step prior to con;ugation with a targeting moiety. However, where a targe=ing moiety is unreactive with the conversion reagents and ur.af=ected by the reactior- conditions, it is possible to generate a conjugation group in the presence of the targeting moiety.
An electrophilic conjugation group may react directly with a nucleophile, either through nucleophilic substitution or nucleophilic addition. In the present invention, electrophilic conjugation groups react with the targeting moiety acting as the nucleophile. A targeting moiety may naturally possess nucleophilic group(s) . For example, a targeting moiety may contain an amino group cr a sulfhydryl group. Alternatively, a targeting moiety may have been modified to contain nucleophilic group(s). Procedures fer modifying molecules to contain nucleophilic groups are well known to those in the art (see, e.g., catalog of Pierce Chemical Co., Rockford, IL, and U.S. Patent Nc. 4,659,839).
Electrophilic groups which provide conjugation through nucleophilic substitution include those groups which contain substituents which are readily displaced. Such readily displaced substituents are commonly referred to as leaving groups. Leaving groups include halides which are readily displaced from alkyl halides and alphahalo carbonyl compounds, and carboxylate and stabilized oxyanions which are readily displaced from carbonyl-containing groups such as anhydrides and active esters, respectively. For example, in addition to halide ion leaving groups such as iodide, bromide, and chloride ions, other leaving groups include carboxylate ions such as acetate and trifluoroacetate and phenolate ions such as phenolate and p-nitrophenolate as well as tosylates and mesylates. Suitable active ester groups include N-hydroxysuccinimidyl, tetrafluorophenyl, nitrophenyl, and 1-hydroxvbenzotriazolyl.
Electrophilic groups which provide conjugation through nucleophilic addition include those groups which contain unsaturated carbon atoms susceptible to nucleophilic add_tion.
Suitable electrophilic carbon species include thiocyanates, isocyanates, isothiocyanates and maleimides.
As mentioned above, a conjugation group capable of reacting directly with a targeting moiety may be prepared by conversion of a weaker electrophilic or nucleophilic group to a stronger one. For example, a carboxylic acid group is a precursor group which may be activated, (e.g., by conversion into an active ester conjugation group capable of reaction with targeting moieties as described above) . Another example of a conversion to a strong electrophilic group is deprotection of a phenylsulfonyl succinimide to provide a maleimide capable of reaction with nucleophilic targeting moieties as described above.
The conjugation group may also be a nucleophilic group, such as an amino or sulfhydryl group. Such a nucleophile is capable of reacting with an electrophilic targeting moiety, such as one that naturally possesses electrophilic group(s) or one that has been modified to include electrophilic group(s).
For example, a targeting moiety may contain an active eszer or a maleimide group. Alternatively, procedures for modifying molecules to contain electrophilic groups are well known to those in the art (see, e.g., catalog of Pierce Chemical Co., Rockford, IL, and U.S. Patent No. 4,671,958).
Alternazively, Z may be a targeting moiety rather than a conjugation group. A "targeting moiety" in the compounds of the present invention has the functional property that it binds to a defined target cell population, such as tumor cells. Preferred targeting moieties useful in this regard include proteins, peptides, antibody and antibody fragments, hormones, and vitamins such as biotin. Proteins corresponding to known cell surface receptors (including low density lipoproteins, transferrin and insulin), fibrinolytic enzymes, anti-HER2, platelet binding proteins such as annexins, aviciin, streptavidin, and biological response modifiers (including interleukin, interferon, erythropoietin, colony-stimulating factor, TNF-tissue necrosis factors and similar cytokines) are also preferred targeting moieties. Also, anti-EGF receptor antibodies, which internalize following binding to the receAtor and traffic to the nucleus to an extent, are preferred targeting moieties for use in the present invention to facilitate delivery of Auger emitters and nucleus binding drugs to target cell nuclei. Oligonucleotides, e.g., antisense oligonucleotides that are complementary to portions of target cell nucleic acids (DNA or RNA), are also useful as targeting moieties in the practice of the present invention.
Oligonucleotides binding to cell surfaces are also useful.
Analogs, including those of tne above=listed targeting moieties, that retain the capacity to bind to a defined target cell population may also be used within the claimed invention.
In addition, synthetic or recombinant targeting moieties may be designed and produced.
Functional equivalents of the aforementioned molecules are also useful as targeting moieties of the present invention. An example of a targeting moiety functional equivalent is a"mimetic" compound, which is an organic chemical construct designed to mimic the proper configuration and/or orientation for targeting moiety-target cell bindi-ng.

Another example of a targeting moiety functiona'- equivalent is a short polypeptide designated as a "minimal" polypeptide.
Such a polypeptide is constructed using computer-assisted molecular modeling and mutants having altered bind.ing affinity of the targeting moiety.
As disclosed above, preferred targeting moieties of the present invention are proteins, antibodies (polyclonal or monoclonal), peptides, oligonucleotides or the like.
Polyclonal antibodies useful in the practice of the present invention are polyclonal (Vial and Callahan, Univ. Mich. Med.
Bull. 20:284-6, 1956), affinity-purified polyclonal or fragments thereof (Chao et al., Res. Comm. in Che:n. Path. &
Pharm. (:749-61, 1974).
Monoclonal antibodies useful in the practice of the present invention include whole antibody and fragments thereof. Such monoclonal antibodies and fragments are producible in accordance with conventional techniques, such as hybridoma synthesis, recombinant DNA techniques and protein synthesis. Useful monoclonal antibodies and fragments may be derived from any species (including humans) or may be formed as chimeric proteins which employ sequences from more than one species. See, generally, Kohier and Milstein, Nature 256:495-97, 1975; Eur. J. Inmmunol. 6:511-19, 1976.
Human monoclonal antibodies or "humanized" murine antibody are also useful as targeting moieties in accordance with the present invention. For example, a murine monoclonal antibody may be "humanized" by genetically recombining the nucleotide sequence encoding the murine Fv region (i.e., containing the antigen binding sites) or the complementary determining regions ("CDR's") thereof with the nucleotide sequence encoding a human constant domain region and an Fc region (i.e., human framework), e.g., in a manner similar to that disclosed in U.S. Patent Nos. 4,816,397, 4,816,567, 5,530,101 and 5,585,089. Some murine residues may also be retained within the human variable region framework domains to WO 98/43678 PCT/US98/05858.

ensure proper target site binding characteristics. Humanized targeting moieties are recognized to decrease the -immunoreactivity of the antibody or polypeptide in the host recipient, permitting an increase in the half-life and a reduction in the possibility of adverse immune reactions.
Another preferred targeting moiety of the present invention is an annexin and other platelet binding proteins, such as PAP-1 (Placental Anticoagulant Protein or Annexin V).
Annexins are (with the exception of annexin II), single-chain, non-glycosylated protein of approximately 36 kilodaltons. In the presence of calcium, these proteins have an especially high affinity for negative'-y-charged phospholipids, such as phosphatitylserine.
As mentioned above, W is a hvdrolvzabie group. As used herein, the term "hydrolyzable group" refers to any neutrai organic group that provides a charged grouc upon hydrolysis.
The hydrolysis may be chemical or enzymatic in nature.
Examples of hydrolyzable groups include esters, imidates, and nitriles which may be hydrolyzed to carboxylic acids; and carbamates which may be hydrolyzed to amines.
Referring to the above formula, the distance by which the chelating nitrogen atoms are separated may be increased by interposing a methylene group, -CH2-, between the carbon atoms bonded to the nitrogens depicted. When no methylene group is interposed, represented in the above formula where n = 0, the chelating nitrogens are separated by twc carbon atoms. When r.
= 1, the interposed methylene group may be substituted with R3.
R3 may be hydrogen, a lower alkyl group, an alkyl group, an alkoxy group, a halogen, a hydroxyl group, a nitro group, -(CH2) n,-Z or -(CH Z),-W- As used throughou;., a lower alkyl group is an alkyl group of hydrocarbon radicals having from 1-1 0 carbon atoms, and physiologically acceptable salts of the acid radicals which includes a substituted lower alkyl. A
substituted lower alkyl group is a lower alkyl group that bears a halogen, perhaloalkyl, hydroxyl or alkoxy substituent;
an alkoxy group is anv alkoxy group of C6 or less. Suitable halogens include fluorine, chlorine, bromine and iodine.
R, and R5 may be attached at one or more of the aromatic 5 ring positions, preferably the ring carbon atoms. R4 and R5 are independently selected from hydrogen, a lower alkyl group, an alkoxy group, a halogen, a hydroxyl group, a nitro group, -(CH2)m-Z and -(CHz)m-W. For R, and R5, preferred groups include lower alkyl groups such as methyl, alkoxy groups such 10 as methoxy, and halogen groups such as fluorine. Preferred Z
groups include active esters such as N-hydroxysuccinimide esters and maleimides. Preferred W groups include ester and carbamate groups, such as ethyl esters and ethyl- carbamates.
Preferably, such preferred alky: groups, alkoxy groups, and 15 ester groups are substituted at the aromatic ring carbon ortho or para to the chelating nitrogen depicted in formula I above.
R6 and R, may be independently a hydrogen, lower alkyl, aikoxy, halogen, hydroxyl, nitro, -(CH,)õ-Z, -(CH2).,-W and R12 , where Q represents a multivalent acid -- ( CH2 ) P C-Q

functionality capable o: coordinating with meta'L ions, and p 0 to 1; R1.2 and R13 are independently selected from hydrogen, hydroxyl, carboxyl, phosphor.ic, and hydrocarbon radicals having from 1-10 carbor. atoms, and physiologically acceptable salts of the acid radicals, and R,; and R1, rnay be the same as or different from one another. In one embodiment, R, may be hydrogen when R6 is R12 and Q is a phosphon'-c or a ,-- (CH,) p C-Q

carboxylic acid and R6 may be hydrogen when R, is qj~
, -~
- ( CH2 ) p C-Q

and Q is a phosphcnic or a carboxylic acid, but R6 and R, cannot both be hydrogen simultaneously. As noted above, Q
represents a multivalent acid functionality. As used herein, the term multivalent acid functionality refers to any multivalent acid capable of coordinating a metal ion known to one of ordinary skill in the art. In preferred embodiments, R6 or R7 or both bear a Q containing substituent. Preferred multivalent acids are the following: a phosphonic acid, a carboxylic acid, a thioacetic acid and a sulfonic acid.
Particularly preferred are a phosphonic acid and a carboxylic acid. The multivalent acid provides extra donor atoms which allow for binding of a metal through coordination of such donor atoms, thereby providing for a versatile chelation compound for diagnostic and therapeutic use.
The compounds of the present invention typically have one or more Q, Z and/or W groups. For example, a compound may have one Z or one W or one Q, or a combination of all three or some lesser combination. Alternatively, for example, a compound may have multiple Z and/or multiple W groups, and/or multiple Q groups.
A and A' may be independently selected from nitrogen, oxygen and sulfur. Where a sulfur is present, it may bear a hydrogen or a sulfur protecting group. Where A and A' are both sulfur, they may be joined together by a bond or any sulfur protecting group known in the art. Where an oxygen or a nitrogen is present, it may bear a hydrogen. Where A or A' is nitrogen, A may bear R9 or R1, or both and A' may bear R. or R11 or both, wherein R9, R9, R1, and Rl; are independently selected from a lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2) õ-Z, -(CH,),,-W and R., , where Q represe.~.ts a Ri3 multivalent acid functionality capable of coordinating with metal ions, and p = 0 to 1; R:2 and R13 are independentlv selected from hydrogen, hydroxyl, carboxyl, phosphonic, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals, and R1,, and R~3 may be the same as or different from one another; R9 and Rlo may be joined to form a cyclic anhydride or R9 and R:1 may be joined to form a cyclic anhydride. Where A and A' are both nitrogen, Rlo and R:: may be joined to form T, where T
is CH (CH) n CH - and n is 0 to 1. R1' and R,' may / I , R ' RZ

3' be independently selected from hydrogen, =0, and -(CHz),-W, or R,' and R,' are taken together tc foa a cyc'_i:.
anhydride or a benzene ring. R3' is selected from hycroce.~., lower alkyl, substituted lower, alkoxy, perha:oalkoxy, perhaloalkyl, halogen, hydroxyl, nitro, -(CH,),-Z and -(CH2)õ-W.
In a preferred embodiment where A and A' are both sul=ur, the sulfur atoms are joined together by a bond thus forming a disulfide. In a preferred embodiment where A and A' are both nitrogen, Rlo and R1: are joined to form T where n is either 0 or 1 and Re and R9 are R1: , where Q represents - ( CH2 ) P C-Q
Ri3 multivalent acid functionality capable of coordinating with metal ions, and m= 0 to 1; R12 and R1J are independently selected from hydrogen, hydroxyl, carboxyl, phosphonic, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals, and R.-and R13may be the same as or different from one another.
The chelation compounds of the present invention ma,/ be categorized by the number and type of chelating atoms (i.e.
NxSyO, where x is 2 to 4, y is 0 to 2, and z is 0 to 2) . For example, where both A and A' are nitrogen, the chelation compounds of the present invention are able to bind a metal through coordination with all four nitrogen atoms. Such a chelating compound may be referred to as an "N," (N,So"J,)) compound. In another embodiment, both A and A' are sulfur, resulting in the capacity for metal chelation through two nitrogen atoms and two sulfur atoms, and thus providing an "N2S," (N2SØ) chelating compound. Alternatively, A may be nitrogen and A' may be sulfur or A may be sulfur and A' may be nitrogen. Either of these embodiments are capable of metal chelation involving three nitrogen atoms and a single sulfur atom, an "N3S" (N3S;Oo) chelating compound. In another embodiment, A and/or A' may be oxygen atoms (e.g., hydroxyl groups). Where both A and A' are oxygen, an "N2O." (N:S~O-) chelating compound results. Other embodiments include "N30"
(N3S0)O.) and "N2SO" (N2S:O:) chelation compounds where cne of either A or A' is oxygen and the other is nit_ogen or sul=ur, respectively.
In a preferred embodiment of the presen-I invention, the chelation compounds are able to bind a metal radionuclide with the donor atoms providing up to eight coordination sizes. For example, A and A' are both nitrogen, Rlo and R;; may join the two nitrogen atoms, through the formation of T to create a cyclic "N," (N,SOOo) chelation compound and wherein R6, Rõ Rg and R9 may be R1z ; wherein Q is preferably a - (CH2) p C-Q

multivalent acid functionality, such as a phosphonic and/or a carboxylic acid. Thus, in addition to the four chelatina atoms of nitrogen, the oxygen atoms of the multivalent acid functionality provide up to four additional coordination sites, thereby expanding the type of radionuclide thaz is useful in this invention (e.g., Indium and Yttrium).
As noted above, the sulfur atoms of the chelaticn compounds may bear sulfur protecting groups. Suitable sulfur protecting groups include any of the alkyl, acyl, and aryl groups, disulfides and bunte salts known by those of ordinary skill in the art. Preferred sulfur protecting groups are those that result in the formation of thioacetal, hemithioacetal, thioketal, hemithioketal, thioester or acetamidomethyl substituent. Particularly preferred groups include p-anisylidine, acetonyl, tetrahydrylfuranyl, ethoxyethyl, tetrahydrylpyranyl, acetamidomethyl and derivatives thereof. When conjugating a chelating compound of the present invention to a targeting moiety, the protecting groups may be removed just prior to metal complexation or during the radiolabeling reaction.
An acetamidomethyl sulfur-protecting group is represented by the following formula, wherein the sulfur atom shown is a sulfur donor atom of the chelating compound:
I
S
I

\ ~) The acetamidomethyl group is displaced from the chelating compound during radiolabeling conducted at about 50 C in a reaction mixture having a pH of about 3 to 6.
When hemithioacetal protective groups are used, each sulfur atom to be protected has a separate protective group attached to it, which together with the sulfur atom defines a hemithioacetal group. The hemithioacetal groups contain a carbon atom bonded directly (i.e., without any intervening atoms) to a sulfur atom and an oxygen atom, i.e., I

Preferred hemithioacetals generally are of the foll-owing formula, wherein the sulfur atom is a sulfu= atom of the chelating compound, and a separate protecting group is attached to each of the sulfur atoms on the chelating 5 compound:

OR a I
Rb C R' S

wherein Ra is a lower alkyl group, preferably of from 2-5 10 carbon atoms, and Rb is a lower alkyl group, preferably o=
from 1-3 carbon atoms. Alternatively, Rd and Rb may be taken together with the carbon atom and the oxygen atom shown in the formula to define a nonaromatic ring, preferably comprising from 3-7 carbon atoms in addition to the carbon and oxygen 15 atoms shown in the formula. R' represents hydrogen or a lower alkyl group wherein the alkyl group preferably is of from 1-3 carbon atoms. Examples of such preferred hemithioacetals include, but are not limited to:
H, ~ 'CH2 \ ,CHZ
~C~
H S

I
TetrahydroLurany_ / CZ

\ C ,CH2 H3C \S

2-methyl tetrahydrofuranyl H2C IH~
H2C~ C 0 I \
H
S

I
Tetrahydropyranyl H3Cll-l CH, 1' HjC",~ C /0 1 ",~H
S
I
Ethoxyethyl H, ~
H2C~ i H2 HZ 1C~ O

S

2- methyl tetrahydropyranyl In one enzbod_ment of the present invention, the sulfur protecting groups may join the two su-1fur chelating atoms.
Preferred embodiments of the sulfur protecting groups include thioketals and thioacetals, which may be prepared by condensation of the sulfur containing chelating compound with ketones and aldehydes, respectively. These par=icular sulfur protecting groups are represented by the following formula, wherein the sulfur atoms shown are the sulfur donor atom of the chelating comoound:

I I
S
/ C \
Rd Re In the formula, R and Re are independently selected from hydrogen, lower alkyl groups (preferably methyl or e-zhyl), lower alkoxy groups (preferably containing one or two carbon atoms), aryl groups, or taken together form a cyclic group (preferably a cyclopentane or cyclohexane ring).
These sulfur-protective groups are displaced during the radiolabeling reaction, conducted at acidic pH, in what is believed to be metal-assisted acid cleavage. Covalent bonds form between the sulfur atoms and the metal radionuclide. A
separate step for removal of the sulfur-protective groups is not necessary. The radiolabeling procedure thus is simplified. In addition, the basic pH conditions and harsh conditions associated with certain known radiolabeling procedures or procedures for removal of other sulfur protective groups are avoided. Thus, base-sensitive groups on the chelating compound survive the radiolabeling step intact.
Such base labile groups include any group which may be destroyed, hydrolyzed, or otherwise adversely affected by exposure to basic pH. In general, such groups include esters, maleimides, and isothiocyanates, among others. Suc:. groups may be present on the chelating compound as conjuga=ion groups.
The aromatic ring atoms designated as X, Y, X' and Y' are independently selected from carbon, nitrogen, sulfur and oxygen to independently form five or six member rings, wherein the remaining ring atoms are carbon. The aromatic rings containina X and Y or X' and Y' are selected independently.
For example, one ring may be a five member ring and the other a six member ring. For six member rings, where X, Y, X' and Y' are all carbon, the aromatic rings are benzene type rings.
Where X, Y, X' and Y' are all nitrogen, the aromatic rings are pyrimidine type rings. Where one of X or Y and one of X' or Y' are nitrogen, the aromatic rings are pyridine tvpe rings.
For five member rings where X, Y, X' and Y' are all nitrogen, the aromatic rings are imidazole or pyrazole type rings. Where one of X or Y and one of X' or Y' are sulfur, the aromatic rings are thiophene type rings. Where one of X or Y
and one of X' or Y' are sulfur and nitrogen, the aromatic rings are thiazole or isothiazole type rings, where on of X or Y and one of X' or Y' are oxygen, the aromatic rings are furan type rings, where one of X or Y and one of X' or Y' are oxygen and nitrogen, the aromatic rings are oxazole or isoxazole type rings.
Preferred embodiments of the aromatic rings designateo' X, Y, X' and Y' include benzene, pyrimidine, pvridine and thiophene, the most preferred being benzene or thiophene.
These particular aromatic rings are interchangeable within the chelating compound formula because they are either structurally related or contribute similar properties, e.g., spatial configuration, electronic resonance and inductive properties (i.e., electron withdrawing and donating effects).
The chelation compounds and metal chelates of the present invention may also be asymmetric with respect to the nature of the aromatic rings. For example, the aromatic rings are a combination of benzene and pyr_dine types where X and Y are both carbon and either X' or Y' are both carbon, o= either X or Y is nitrogen and X' and Y' is nitrogen, or either X or Y is nitrogen and X' and Y' are both carbon. In another embodiment, the aromatic rings are a combination of benzene and py=imidine types where X and Y are both ca_bon and X' and Y' are both nitrogen, or X and Y are both nit:oaen and X' and Y' are both carbon. In another embodiment, the aromatic rings are a combination of pyridine and pyriTidine types where either X or Y is nitrogen and X' and Y' are bcth nitrogen, or X and Y are both nitrogen and either X' or Y' are n:t:ogen. In another embod--ment, the aromatic rings are a comb:naticr, ef benzene and thiophene types where either X or Y are both carbon and either X' or Y',is sulfur, or either X or Y is sulfur and X' and Y' are both ca--bcn. In another embodiment, the aromatic rings are a combination of pyridine and thiophene types whether either X or Y is nitrogen and one of which is carbon and X' or Y' is sulfur and one of which is carbon, or either X
or Y is sulfur, one of which is carbon and either X' or Y' is nitrogen, one of which is.carbon. Further variations of the aromatic rings of the presently identified chelation compounds will be evident to one of ordinary skill in the based on the present disclosure in view of the art.
As noted above, in addition to providing chelation compounds, the present invention provides radionuclide metal chelate compounds wherein a metal is chelated (complexed).
5 The chelation compounds of the present invention rapidly form stable metal complexes (radionuclide metal chelates) when reacted with a metal.
The preferred radionuclide metal chelate compound (complexes) of the present invention have the formula (II) Rl I R2 N. ,N
M
Ra X A' ,, X' R5 wherein R1-R11, n, X, X', Y, Y' are described above. A and A' may be independently selected from nitrogen, sulfur and oxygen. M is a radiometal or a radionuclide metal oxide or nitride, capable of being chelated by a compound of the 15 present invention. Preferred metals and metal oxides or nitrides include radionuclides of copper, yttrium, ruthenium, technetium, rhodium, palladium, gadolinium, samarian, holmium, ytterbium, lutetium, indium, rhenium, gold, lead and bismuth.
Particularly preferred are 64Cu, 67Cu, 90Y, 97Ru, 99'"Tc, losRh, 20 109Pd, 111In, 153Sm, 159Gd, 166Hp, 175Yb, 1'%Lu, 1e6Re, 19eRe, 196Au, 199Au~ z03Pb~ Z12Pb and zlzBi.

= Methods for preparing these isotopes are known.
Molybdenum/technetium generators for producing 99'"Tc are commercially available. Procedures for producing 186Re include 25 the procedures described by Deutsch et al. (Nucl. Med. Biol.
13(4) :465-477, 1986) and Vanderheyden et al. (Inorganic Chemistry 24:1666-1673, 1985) (see also U.S. Patent No.
5,053,186), and methods for production of laeRe have been described by Blachot et al. (In~_-I. J. of Applied Radiation and Isotopes 20:467-470, 1969) and by Klofutar et al. (J. of Radioanalytical Che:n. 5:3-10, 1970) (see also U.S. Patent No.
4,859,431). Production of l09Pd is described in Fawwaz et al.
(J. Nucl. Med. 25:786, 1984) . Production of 21ZPb and ~=2Bi is described in Gansow et al. (Amer. Chem. Soc. Syrnp. Ser 241:215-217, 1984) and Kozah et al. (Proc. Nat1. Acad. Sci.
USA 83:474-478, 1986). Production of 90Y, a particle emitting therapeutic radionuclide resulting from transmutation processes (without non-radioactive carrier forms present), is commercially available from several sources, including Pacific Northwest National Laboratory, located in Richiand, Washington; Nordion International Inc., locatec' in Kanata, Ontario, Canada and by Du Pont as NEN Research products located in North Billerica, Massachusetts. Production of =53Sm is described in Goeckeler et al (Nucl. Med. Bioi., Voi. 20, No. 5, pp. 657-661, 1993) . 111In is commercially available as INDICLOR'a' supplied by Amersham Healthcare located in Arlington Heights, Illinois. 49mTC is preferred for diagnostic use, and the other radionuclides listed above are preferred for therapeutic use.
In one embodiment of the present invention, chelation compounds of the invention including acetamidomethyl and/or hemithioacetal sulfur protective groups are radiolabeled with a metal radionuclide by reacting the compound with the radionuclide under conditions of acidic pH. It is believed that the acidic pH and the presence of the metal both contribute to the displacement of the sulfur protective groups from the chelating compeund. The radionuclide is in chelatable form when reacted with the chelation compounds of the invention.
In the case of technetium and rhenium being in "chelatable form" generally requires a reducing step. A
reducing agent will be employed to reduce the radionuclides (e.g., in the form of pertechnetate and perrhenate, respectivelv) to a lower oxidation state at which chelation wil'_ occur. Many suitable reducing agents, and the use thereof, are known . (See, for example, U.S. Patent Nos.
4,440,738; 4,434,151; and 4,652,440.) Such reducing agents include stannous ion (e.g., in the form of stannous salts such as stannous chloride or stannous fluoride), meta llic tin, ferrous ion (e.g., in the form of ferrous salts such as ferrous chloride, ferrous sulfate, or ferrous ascorbate) and many others. Sodium pertechnetate (i.e., 9aiTc0,'' which is in the +7 oxidation level) or sodium perrhenate ( i. e., leeReO,-, 186Re0,'1) may be combined simultaneously with a reducing agent and a chelating compound of the invention, in accordance w:th the radiolabeling method of the invention, to fcrm a chelaze.
Preferably, the radionuclide is treated with a rec'ucing agent and a compiexing agent to form an intermediate comp_ex (i.e., an "exchange complex"). Complexing agents are compounds which bind the radionuclide more weakly than do the chelate compounds of the invention, and may be weak chelators.
Any of the suitable known complexing agents may be used, including gluconic acid, glucoheptonic acid, tontanic acid, methylene disphosphonate, glyceric acid, glycolic acid, mannitol, oxalic acid, malonic acid, succinic acid, bicine, N,N'-bis(2-hydroxy ethyl) ethylene diamine, citric acid, ascorbic acid and gentisic acid. Good results are obtained using gluconic acid or glucoheptonic acid as the Tc-complexing agent and citric acid for rhenium. When the radionuclide _n the form of such an exchange complex is reacted with the chelation compounds of the invention, the radionuclide w4 transfer to the chelation compounds., which bind the radionuclide more strongly to form chelates of the invent_en.
In some instances, heating is necessary to promete transfer of the radionuclide. Radionuclides in the form of such complexes also are considered to be in "chelatable form" for the purposes of the present invention.
Y-90 is a particularly preferred radionuclide for -------------therapy, because it exhibits favorable nuclear properties including high specific activity, long path length with respect to deposition of radiation in tissue, high equilibrium dose constant and favorable half-life properties. More specifically, the beta emission of Y-90 (Beta,õ=0.937 MeV) makes it one of the most energetic of all beta emitters. The X90 value of Y-90 is 5.34 mm (i.e., 90% of the energy emitted from a point source is absorbed in a sphere of 5.34 mm radius). Y-90 has a high equilibrium dose constant or mean energy/nuclear transition, Delta = 1.99 Rad-gram/microcurie-hour, and a 64 hour half-life suitable for targeted therapy.
Y-90 can be manufactured at high specific activity and is available as a generator product. Specific advantages of Y-90 are (1) that it has the capability to kill neighboring target cells not directly targeted by conventional methods (2) that more radiation is deposited per microcurie localized than for other beta emitters of lower mean particle energy (provided that a sufficiently large target volume is available).
Chelates of 212 Pb, 212 Bi, 109 Pd, Cu64 and Cu6' may be prepared by combining the appropriate salt of the radionuclide with the chelating compound and incubating the reaction mixture at room temperature or at higher temperatures. It is not necessary to treat the lead, bismuth, palladium and copper radioisotopes with a reducing agent prior to chelation, as such isotopes are already in an oxidation state suitable for chelation (i.e., in chelatable form). The specific radioiabeling reaction conditions may vary somewhat according to the particular radionuclide and chelating compound involved.
In another embodiment of the present invention, where the sulfurs are protected by formation of a disulfide bond, chelation compounds of the invention are radiolabeled following reduction of the disulfide bond under mild conditions. For example, the disulfide may be reduced with SnCl2 under conditions which do not reduce disulfides on proteins such as antibodies.

The chelation compounds and metal- chelates of the present invention have a variety of uses, although certain uses are preferred depending upon the particular embodiment. In one embodiment of the present invention, the chelation compounds can be employed in the pretargeting methods as described in U.S. Patent No. 5,608,060.
In another embodiment of the present invention, the chelation compounds and the radionuclide metal chelates are either reactive with a targeting moiety, or are conjugated to a targeting moiety. These compounds may be generally represented by the above-described compounds which bear the group Z. A chelating compound or a metal chelate that is reactive with a targeting moiety bears at least one conjugation group Z. Such conjugation groups include those described above (e.g., an active ester or a maleimide).
Alternatively, the chelating compound or metal chelate may be conjugated to a targeting moiety Z. Such targeting moieties include those described above (e.g., proteins and antibodies).
The preparation of representative chelation compounds that are reactive with targeting moieties is presented in the examples below. The preparation of representative radionuclide metal-targeting moiety conjugates is also presented in the examples below.
In the practice of the present invention, metal chelate-targeting moiety conjugates may be prepared by complexation of the radionuclide metal either before or after the chelating compound is conjugated to the targeting moiety. More specifically, a conjugate may be "pre-formed" or "post-formed," depending upon whether the chelating compound and targeting moiety are joined after or before the complexation of the radionuclide metal. A pre-formed conjugate comprises a chelating compound of the present invention that is first labeled with a radionuclide metal and then is conjugated to a targeting moiety. A post-formed conjugate comprises a chelating compound of the present invention that is first conjugated to a targeting moiety and then is labeled with a radionuclide :netal. Thus, for pre-formed conjugates, the radionuclide is added to the chelating compound crior to the addition of the targeting moiety, whereas, for post-formed 5 conjugates, the radionuclide is added after the addition of the targeting moiety. The final conjugate is the same regardless of how formed.
Generally, the chelation compounds of the present invention that are either reactive with targeting moieties or 10 are conjugated to targeting moieties may be represented by the formula (I) above, where the specific embodiments of the elements of the formula include the following:
R. and R, may be independently hydrogen (H) , an ox.y group (=0); or -(CH)~,-Z where m is 0-10 and Z represents a 15 conjugation group or targe*_inc moiety; or R, and R, may be taken together to form a cyclic anhydride or a benzene ring.
The distance between the chelating nitrogen atoms of formula (I) may be varied bv the impositic:, of a methylene group. When imposed, the methylene group may be substituted 20 with R3.
R3 may be hydrogen, a lower a'Lkyl grouo, an alkoxy group, a halogen, a hydroxyl group, a nitro group, or -(CHz).,-Z.
R4 and RS may be attached at one or more cf the aromatic ring positions, preferably the ring carbon atoms, and are 25 independently selected from hydroger., a lower alkyl group, an alkoxy group, a halogen, a hydroxyl group, a nitro group, and - (CH,),,-Z .
R6 and R, are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH,),-Z, and R1~"
- (CHI) P C-Q

30 where Q represents multivalent acid functionality capable of coordi nating with metal ions, and m = 0 to 1; RiZ and R:3 are independently selected frem hydrogen, hydroxyl, carboxyl, phosphonic, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts o-ff the acid radicals, and R,2 and R13 may be the same as or different from one another.
The chelation compounds reactive with or conjugated to targeting moieties have at least one Z, but may contain more than one Z. For example, any two groups selected from R;-RS
may be Z.
A, A', X, X', Y, Y' and n are as described above for formula ( I ) .
Similarly, the radionuclide metal chelate compcunds of the present invention that are either reactive wit~ targec=ng moieties or are conjugated to targeting moieties mav be represented by the formula (II). The speciffic embodiments cf those elements of the formula denoted by R1-Rs, n, X, X', Y, and Y' are as described immediately above for the c~e=ation compounds. M is a radionuclide, radionuclide meta= oxide or radionuclide metal nitride. The metal chelate compounds reactive with or conjugated to targeting moieties have at least one Z, but may contain more than one Z.
In a preferred embodiment, the compounds of the present invention are "N4" (N4So00) chelation compounds and metal chelates. Therefore, for preferred chelation compounds and metal chelates, A and A' are nitrogen. For particularly preferred chelation compounds, A and A' are nitrogen atoms joined together by a bond, i.e., Rlo and R:1 form T, the chelation compounds are tetraazacyclic, a tetradectane system.
Preferred compounds of the present invention have X, Y, X' and Y' as carbon, nitrogen and sulfur. For the metal chelates of the present invention, technetium (e.g., 99mTc) and indium (e.g., '==In) are the preferred metals for diagnostic purposes, and rhenium (e.g., '-86Re and 'BBRe) and yttrium (e.g., 90Y) are the preferred metals for therapeutic purposes.
Further, in a prefzrred embodiment, the compounds of the present invention, which are reactive with targeting moieties, possess a single conjugation group. A preferred conjugat4on group is the N-hydroxysuccinimide ester group.
In a preferred embodiment, in addition to the above-mentioned preferences, the conjugation group is an aromatic ring substituent, i.e., either R4 or R5 is -( CHZ )õ-Z . For one such preferred embodiment, n = 1, R1-R, are hydrogen, and R. is -(CH2)R,-Z, where m= 0 and Z is an active ester such as an N-hydroxysuccinimide ester. Alternatively, the conjugation group may be a substituent of the carbons linking the chelating nitrogens, i.e., R1-R3 . In one such preferred embodiment, n = 1, R, or R2 are -(CHZ),-Z where m = 0 and Z is an N-hydroxysuccinimide ester, R; is hydrogen, and R, and RS
are hydrogen. In another such preferred er.ib cdiment, n= 1, R.
and R2 are hydrogen, R3 is -(CH.).,-Z as descr:bed :mmediately above, and R, and R. are hydrogen. R6, R-, Ry and R9 may be R12 where Q represents multivalent acid - (CH,) P C-Q

functionality capable of coordinating with metal ions, and m=
0 to 1; R1. and R13 are independently selected from hydrogen, hydroxyl, carboxyl, phosphonic, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals, and R12 and R13may be the same as or different from one another.
In another preferred embodiment, in the "N," (N4Sc)O3) compounds of the present invention the conjugation group is an anhydride, i.e., R, and R:o and Ro and R. are taken together in a vicinyl configuration, to form a cyclic anhydride, -(CHZ),n-Z, where m = 1 and Z is a carboxylic acid anhydride resulting from vicinyl dicarboxylic acids. In one such embodiment, in addition to the above-mentioned preferences, R1-RS are hydrogen, n= 1, R; and R- are R12 , where Q represents - (CH2) P C.

multivalent acid functionality capable of coordinat-ing with metal ions, and p = 0 to 1; R12 and R,, are independent'_y selected from hydrogen, hydroxyl, carboxyl, phcsphonic, and hydrocarbon radica's having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals, and R:z and R:jmay be the same as or different from one another.
In another preferred embodiment, the conjugation group is an anhydride, i.e., R, and R 2 are taken together to form a cyclic anhydride. In one such embodiment, in addition to the above-mentioned preferences, R1 and R, are taken together to form a cyclic anhydride, n = 0, and R, and R. are fluorine.
For the compounds of the present invention which are conjugated to targeting moieties, preferred taryeting mcieties include proteins such as antibodies and annexin as wel'_ as binding proteins such as avidin and streptavidin.
In another aspect of the present invention, the c::elat=on compounds and the radionuclide metal chelate compounds are used in radiopharmaceutical applications without the necess-ty for a conjugation grouo or targeting moiety. Such chelating and metal chelate compounds are useful by virtue of their lipophilic properties and may be generally represented by the above-described compounds which bear hydrolyzable group W.
Generally, the chelation compounds of the present invention that are usefu; without possessing a conjugating group or targeting moie-ly may be represented by the formula (i) above where the specific embodiments of the elements of the formula include the following.
R1 and R, may be independently hydrogen (H; , an cxy group (=0); or -(CH2),n-W where W represents a hydrolyzable group; or R. and R2 may be ta'.{en together to form a cyclic anhydricie or benzene ring.
The distance between the chelating nitrogen atoms of formula (I) may be varied the imposition of a methylene group, -CH,. When imposed, the methylene group may be substituted with R3.

R3 may be hydrogen, a lower alkyl group, an alkoxy group, a halogen, a hydroxyl group, a nitro group, and -(CHZ),-W.
R4 and R. may be attached at one or more of the aromatic ring positions, preferably the ring carbon atoms, and are independently selected from hydrogen, a lower alkyl group, an alkoxy group, a halogen, a hydroxyl group, a nitro group, or -(CHz);,-W.
The chelation compounds that are useful in the absence of a conjugation group of targeting moiety have at least one W, but may contain more than one W. For example, any two groups selected from R1-R5 may be W.
A, A', X, X', Y, Y', R5, R;, and R9 through R:: and n are as described above for formula (I).
Similarly, the radienuc'_ide metal cheiate compcunds of the present invention tnat are useful without a conjugation group or targeting moiety may be represented by the formula (II) where the specific embodiments of the elements of the formula, R,-R5, R6-R11, n, X, X', Y and Y' are as described immediately above for the chelation compounds. M is a radionuclide, radionuclide metal oxide or radionuclide metal nitride. The metal chelates that are useful in the absence of a conjugation group or targeting moiety have at least one W, but may contain more than one W.
In a preferred embodiment, W is an enzyme hydrolyzable group, such as an ester or a carbamate. Such groups are subject to hydrolysis by esterases commonly found in tissues such as the heart and bone marrow. In a particularly preferred embodiment, the hydrolyzable group is an ethyl ester or ethyl carbamate.
Preferred embodiments of the compounds which possess hydrolyzable groups W include the preferences for M, A, A', X, Y, X' and Y' described above for the compounds which possess a conjugation group or a targeting moiety, Z. In a preferred embodiment, the compounds of the present invention having hydrolyzable groups W possess more than one W.

In one preferred embodiment, in addition to t:ze above-mentioned preferences, the hydrolyzable group is an aromatic ring substituent, i.e., R, and R. are -(CHZ),-W . For one such embodiment, n 1, R,-R3 are hydrogen, and R4 and R5 are -5 ( CHz ),n-W, where m 0 and W is either an ester (i.e., -CO,Et ), a carbamate (i.e., -NH-CO2Et) or a nitrile (-CN).
Alternatively, in another preferred embodiment, where both R4 and R5 are -(CH2),-W as described immediately above, n = 1, either R1 or R2 is an oxy group (=0) and R3 is either hydrogen 10 or - (CHz),-W.
In another preferred embodiment, the hydrolyzable group W
is a substituent of the carbon atoms linking the chelatinC
nitrogens, i.e., one or more of R,-R; is -(CH,)õ-W. For example, in one such preferred embcd:ment, in add_tion t:, the 15 above noted preference, n = 0, R1 and R, are -(CH,) õ-W where m=
0 and W is an ester, and R, and R. are fluo:ine. In another such preferred embodiment, n 1, either R1 or R, is an oxy group (=0) , R3 is -(CH, ) R,-W as described immediatelv above, and R, and R; are 20 methyl. In a further such preferred embodiment, n= 1, R. and R2 are hydrogen, R3 is -(CHZ),,,-W as described above, and R, and RS are methoxy.
The lipophilic properties cf these che-at-'ng and me,:~al chelate compounds are due in part to the hydrophobic nature of 25 hydrolyzable W. As noted above, W ir.cludes any neutral organic group that provides a charged group upon hydrolysis.
Generally, the neutral organic group of W is hydrophobic and imparts lipophilic character to the chelating and metal chelate compounds.
30 The lipophilic compounds of the present invention are particularly useful in vivo where it is desirous to accum=,:late the metal chelates in tissues such as the heart and bone marrow. In such applications, the administered lipophilic metal chelates reach these tissues through the bloodstream 35 and, because of their lipophilic properties, the metal-chelates are abscrbed by these tissues. Once absorbed into the tissues, the metal chelates are subject to hydrolysis where the hydrolyzable group, W (e.g., an ester), which imparted lipophilicity to the chelate is converted to a charged species (e.g., an acid if the ester is a carboxylate ester, and a base if the ester is a carbamate ester) and is thereby prevented from escaping the tissue.
Suitable hydrolyzable groups W included nitriles, carbamates, and esters. Preferred hydrolyzable groups include carbamates and carboxylate esters. Preferred carboxylate esters include methyl, ethyl, propyl and isopropyl esters.
Preferred carbamate esters include methyl and ethyl esters.
The lipophilic metal chelates of the presenz invention, which bear hydrolyzable groups W, may undergo e_ther chemical or enzymatic hydrolysis to yield residually charged metal chelates. To be effective, the metal chelates are resistant to rapid hydrolysis in the bloodstream, but are readily hydrolyzed upon uptake by the tissue of interest. Hydrolysis which occurs in the bloodstream is primarily chemical in nature while tissue hydrolysis is primarily enzymatic.
In one embodiment, the compounds of the present invention are additionally resistant toward chemical hydrolysis. For example, the chelation compounds and metal- chelates that bear ester groups, which are direct2y conjugated to the aromatic ring as either ortho or para substituents relative to the chelating nitrogen, are particularly stable toward chemical hydrolysis. Referring to the above formulas, these preferred compounds are represented by those compounds where R, and/or RS
are -(CHz ) ,-W (m = 0 and W is an ester), and where R, and/or R.
is located ortho or para to the chelating nitrogen.
Such suitably substituted esters are resistant toward chemical hydrolysis by virtue of electron donation from the chelating nitrogen through the aromatic ring to the ester carbonyl group. This dispersal of electron density renders the ester carbonyl relatively electron rich and reduces its reactivity as an electrophile. Because the rate-determining step in ester hydrolysis is the addition of a nucleophilic water molecule to the ester carbonyl, ester carbonyl groups that are less electrophilic react more slowly toward nucleophilic addition. Thus, ester carbonyl groups which are stabilized toward nucleophilic addition by electron donating groups are resistant toward hydrolysis. For these reasons, the above-described esters of the present invention are resistant toward chemical hydrolysis in the bloodstream.
While the efficacy of the administration of the lipophilic compounds of the present invention resides in part in their stability toward hydrolysis in the bloodstream, their ultimate utility as radiooharmaceu*_ica'_ agents relies on their capacity to be taken up and retained by various tissues. The uptake of these compounds into the tissue results from thle particular character of the compounds and the permeabilitv of the tissues toward such compounds.
The compounds of the present invention are retained within a tissue, such as malignant cells, bv conversion of the lipophilic compounds to charged compounds (ionic species) by hydrolysis. The compounds of the present invention, which are resistant to chemical hydrolysis, are readily susceptible to enzymatic hydrolysis. Suitable hydrolyzable groups that are converted to charged compounds by enzymatic action include ester and carbamate groups which are converted to carboxylic acid and amino groups, respectively.
The compounds of the present invention may be taker. up by various tissues, but are primarily intended for the tissues containing malignant cells and activated platelets. The metal chelates of the present invention may be selec'_ive_y taken up by either malignant cell tissue depending upon the nature of the chelate.
The radiolabeled chelates of the present invention have use in diagnostic and therapeutic procedures, both for ir.
vitro assays and for in vivo medical procedures. The radiclabeled chelates ma_v be del ivered (e.g., administered to a warm-blooded animal such as a human) intravenously, intraperitoneally, intralymphatically, locally, or by other suitable means, depending on such factors as the type o*
target site. The amount to be provided will vary according to such factors as the type of radionuclide (e.g., whether it is a diagnostic or therapeutic radionuclide), the route of delivery, the type of target site(s), the affinity of the targeting moiety, if employed, for the target size of interest, and any cross-reactivity of the targeting moiety, if employed, with normal tissues. Appropriate amounts may be established by conventional procedures, and a physician skilled in the field to which this invent_on pertains wil_ be able to deter:nine a suitable amount for a patie:.t. A
diagnostically effective dosage is generally frcm about 5 to about 35 and typically from about 10 to about 30 mCi per 70 kg body weight. A therapeutically effective dosage is generally from about 20 mCi to about 300 mCi or higher. For diagnosis, conventional non-invasive procedures (e.g., gamma cameras) are used to detect the biodistribution of the diagnostic radionuclide, thereby determining the presence or absences of the target sites of interest (e.g., tumors, heart, brain) The comparatively low intestinal localization of the therapeutic radiolabeled chelates of the present invention or catabolites thereof permits increased dosages, since intestinal tissues are exposed to less radiation. The claritv and accuracy of diagnostic images also is improved by the reduced localization of radiolabeled chelates or catabolites thereof in normal tissues via an increase in target to nontarget ratio.
The invention is further described through presentation of the following examples. These examples are offered by way of illustration and not by way of limitation.

3 S EX?:MPLES

Example I
N,N'-Bis(2-diaminophenyl)-1,3-propyldiamino hexaacetic acid 5 NH Z NH HN

OaNO I xylene O 2 Na2CO Q NO Z 0 ZN

NH HN

Pd/C (10$) laNH, _ H2, EtOH H:N

3.
COZH COZH
N N
~-~
BrCH2COOH
' pH 10.0 rN) rN) CO.H CO.IH CO2H CO,H

H,ec3 H2?03 ~
NH HN N N

HCHO, 0 ~
NHz HZ;I rN) rN) H2PO 3 H,PO3 HZP03 H2203 N,N'-Bis(2-dinitronhenvl~-1 3-D_oovid_amine 2:
A stirred susDension of 30.0 g(C.21"1 mole) of 2-nitroaniline 1, 5.0 mL (0.044 mole) of 1,3-diiodopropane and 5 1.90 g (0.023 mole) of sodium bicarbonate in 100 mL xylene was heated at 140-145 C for 36 hours. The reaction mixture was cooled down in an ice bath. The precipitate was collected by filtration. The red solid was washed several times with cold heptane to remove excess unreacted 2-nitroaniline 1 and 2-10 nitro N-methylaniline. The crude product was purified by flash chromatography on a silica gel column using 20% ethyl acetate in hexane as an elution solvent. After 2-nitro-aniline and 2-nitro N-methylaniline were removed from this solvent system, the desired product was then eluted from the 15 column using 50% ethyl acetate in hexane. The fractions containing the product were combined. Solvent was removed under reduced pressure and dried to yield 10.30 g(150) of compound 2.
N, N'-Bis ( 2-diaminoDhenvl) -1, 3-DroDane-.~'.ia*nine 3:
20 1.0 g (0.003 mole) of N, N'-Bis (2-ciinitrophenyl) -1, 3-propyldiamine 2 was taken into a parr hydrogenation bottle.
200 mL of 2% glacial acetic acid in absolute ethanol was added. To the suspension, 0.2 g of 10% palladium on activated carbon was added. The reaction mixture was catalytically WO 98/43678 PCT/US98/05858_ 4i reduced under hydrogen atmosphere at 40 PSI for 4-6 hours.
The solution was filtered and the soivent was removed under reduced pressure and dried. The crude residue was placed in a sodium bicarbonate solution, and the free amine was extracted into methylene chloride three times, each time with 100 mL
volume. The combined organic layer was dried over anhydrous sodium sulfate and filtered. Solvent was removed under:...
reduced pressure and dried to yield crude residue. The crude residue was purified by silica gel column chromatography using 50% ethyl acetate in hexane as an elution solvent. The fractions containing the desired product were combined.
Solvent was removed under reduced pressure and dried to yield 0.53 g(65%) oJE compound 3.
N N'- _s'2-d_ami ~ccnen,/!+-1 3-crcoa.~,e d_aminohexacet_c acid 4 To a stirred suspension of 5.0 g(0.020 mole) of N,N'-Bis(2-diaminoFhenyl)-1,3-propanediamine 3 in 75 mL off distilled water, 20.0 g (0.143 mole) of bromoacetic acid is added and magnetically stirred. The pH of the solution is adjusted to 10.0 with 2.0 N sodium hydroxide and the reaction mixture is heated in an oil bath at 45 C for 16 hours. The pH
is maintained between 9.75 and 10.0 with 5.0 N sodium hydrexide during the entire ccurse cf reaction. The progress of the reaction is monitored by high performance liquid chromatography (HPLC) using PRP-X10C anion exchange column (supplied by Hamilton). Smal: amounts of bromoacetic acid (i.e., 100 to 200 mg) are added to the reaction mixture to drive the reaction to completion. The reaction mixture is diluted with sterile water to 2 liter volume and the pH is adjusted to 6.8 with 6.0 N hydrochloric acid. The conductivity for this solution is 4.89 ms/cm. It is further diluted to 4 liters with sterile water and the pH is adjusted to 8.2 with 2.0 N sodium hydroxide. The measured conductivi-ty is 2.89 ms/cm. This solution is loaded on a.5 x 60 cm column with 900 mL bed volume of AG 1-X2 (Bio-Rad Laboratories, 33 Richmond, CA) (ace'tate form) resin which is prewashed with 1 * TrxAem:rrlr liter 1.3 M acetic acid, 1.5 liter water, 0.5 liter 0.02 N
ammonium acetate pH 7.18 and 4 liter water final eluen: pH
4.28 by fast performance liquid chromatography (FPLC) a~: 40 mL/min. The column is eluted with water and gradually increased the solvent B(1.50 M acetic acid) of the gradient system. Fractions containing the product are pooled and solvent evaporated and dried under high vacuum to give 6.75 g (57%) of compound 4.
N,N'-Bis(2-diaminonhenvl) -1,3-oronane-diamino hexamethvlene phosnhonic acid 5:
25.0 g (0.31 mole) of phosphorous acid and 25 mL of degassed water are taken into a 3 neck round bottom flask equipped with a dropping funnel, a thermometer and a magne*_ically stirring bar. The flask is flushed with n'-_rogen gas and a slow stream of nitrogen is maintained in the f:.ask.
Dissolution of the phosphorous acid is achieved uDcn st_=ring.
30 mL of concentrated hydrochloric acid is added to the reaction mixture and the stirring continued. The drooping funnel is charged with 20.0 g (0.078 mole) of N,N'-bis(2-diaminophenyl)-1,3-propanediamine dissolved in 25 mL water.
The amine solution from the dropping funnel is added dropwise to the stirred acidic solution under nitrogen atmosphere.
After completion of addition, the reaction mixt=.:re is heated under reflux using an oil bath fo: at least 1.0 hour. Then the dropping funnel is charged with formaldehyde 27.2 g(0.938 mole) of a 37% aqueous solution and is added to the reaction mixture dropwise over a 2 to 3 hour time interval. The reaction mixture is continued heating under reflux throughout the entire formaldehyde solution addition period. After completion of all of the formaldehyde solution, the reaction mixture is continued stirring under r?'lux for an addit_onal 3 to 4 hours. The reaction mixture is then allowed to cool and the product N,N'-Bis(2-diaminophenyl)-1,3-propane-diamino hexamethylene phosphonic acid is isolated from the reaction mixture and purified by ion exchange resin chromatography.

Example II
2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane-N, N', N", N"'-tetraacetic acid 7 and 2, 3, 9, 10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane-N,N',N",N"'-tetramethylene phosphonic acid 8 NH HN n NH HN
laNH DMSO 2 H 2N A , Na2C0, NH HN

COOH COOH
N N
BrCH2COOH pH 10.0 N N
r (j ~,) COOH COOH

H,P03 H,PO3 I ~
NH HN N N
H3P03/conc. HC1 NH HN HCHO,A N
H,PO3 H,P03 2,3,9,10-diohenyienvl-1,4,8,11-*_etraazacvclo tetradecane 6:
A stirred solution of 10.0 g (0.039 mole) of N,N'-Bis(2-diaminopheny'_)-1,3-propane-dr.amine 3, 2.30 g (0.008 mole) of 1,3-diiodopropane and 6.50 g (0.08 mole) of sod:um bicarbonate in 100 mL dry dimethyl sulfoxide is heated at 115'C for 4 hours under nitrogen atmosphere. The dimethyl sulfoxide solvent is removed under high vacuum and dried. The crude product is extracted three times each time with 100 mL
methylene chloride by partitioning with water. The combined methylene chloride layer is washed with brine and water. The organic layer is dried over anhydrous sodium sulfate and filtered. Solvent from the filtrate is removed under reduced pressure to yield crude product. The crude residue is purified by flash chromatography on silica gel column using 25% ethyl acetate in hexane as an elution solvent. The fractions containing the product are combined and the solvent removed under reduced pressure and dried to yield 1.20 g(103) of compound 6.
2,3,9,10-diphenvlenvl-1,4,8,11-tetraazacvclo tetraciecane--N,N',N",N"'-tetraacetic acid 7:
To a stirred suspension of 10.0 g (0.034 mole) of 6 in 200 mL distilied water, 40.0 g (0.288 mole) of bromoacetic acid is added. The reaction mixture is stirred magnetically at room temperature. The pH o' the solution is adjusted to-10.0 with 2.0 N sodium hydrexicie and the reaction mixture is heated in an oil bath at 45 C for 16 hours. The pH is maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide 5 during the entire course of reaction. The progress of the reaction is monitored by HPLC using PRP-X100 anion exchangecolumn and small amounts of bromoacetic acid is added to the reaction mixture to drive the reaction to completion. The reaction mixture is di-luted with sterile water to 2 liter 10 volume and the pH is adjusted to 6.8 with 6.0 N hydrochloric acid. The conductivity for this solution is 4.89 ms/cm. It is further diluted to 4 liters with sterile water and the pH
is adjusted to 8.2 with 2.0 N sod_um hydroxide. The measured conductivity is 2.89 ms/cm. This sclution is 1-caded cr. 5 x 60 15 cm column with 900 mL bed volume of AGZ) 1-X2 (acetate form) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 liter water, 0.5 liter 0.02 N ammonium acetate pH 7.19 and 4 liter water final eluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water and gradually increased the 20 solvent B(1.50 M acetic acid) of the gradient svstem.
Fractions containing the product are pooled and solvent evaporated and dried under high vacuum to give 7.10 g(40%) of compound 7.
2 3 9,10-diohenvlenvi-' 4 8,11-tetraazacvclo tetradecane-25 N N' tv'" N~-tetramethvlene ehoschor.ic acid 8:
5.0 g(0.061 mcle) of" phosphorous acid and 1.0 mL of degassed water are taken into a 3 neck round bottom flask equipped with a dropping funnel, a thermometer and a sti= bar.
-The flask is flushed with nitrogen gas and a slow stream of 30 nitrogen is maintained in the flask. Dissolution of the phosphorous acid is achieved upon stirring. 8.0 mL of concentrated hydrochloric acid is added to the reaction mixture and the stirring continued. The dropping funnel is charged with 4.0 g (0.014 mole) of 2,3,9,10-diphenyienyl-35 1,4,8,11-tetraazacyclo tetradecane, 6 dissolved in 10 mL
*Traftwk water. The cyclic amine solution from the dropping funnel is added dropwise to the stirred acidic solution under nitrogen atmosphere. After completion of addition, the reaction mixture is heated under reflux using an oil bath for at least 1 hour. Then the dropping funnel is charged with formaldehyde 5.0 g (0.172 mole) of a 37% aqueous solution and is added to the reaction mixture dropwise over a 2 to 3 hour time period.
The reaction mixture is continued heating under reflux throughout the entire formaldehyde solution addition. After completion of all of the formaldehyde solution, the reaction mixture is continued stirring under reflux for an additional 3 to 4 hours. The reaction mixture is then allowed to cool and the product 2,3,9,10-diphenvlenvl-1,4,8,11-tetraazacyclo tetradecane-N, N', N", N"'-tetramethvlene phosphonic acid 8 is isolated from the reaction mixture and purifie.'. by ion exchange chromatography in 35% yield.

Example III
2,3,8,9,-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane N,N',N",N"'-tetraacetic acid 13 and 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane N,N',N",N"'-tetramethylene phosphonic acid 14 c00H O
cl HOOC Cl NH Z & DMSO NH
aNC Z O1 Na ,CO 3, 0 NH, /MF O COOH

NOZ
NH HN

O ::::, 0$) Cu/CuI,HOAc, HZ
Na,C03 NOZ OZ:I
].4.
COOH coox c-,-.
NH HN
-- C. DMF, Na:CO3 a ~- Cu, CuI, Q

~

COOH COOH COOH
COOH
JNH
HN N
-- BrCHZC00H ~ c - pH 10,~
HN N N

COOH
COOH COOH COOH
12 ~

COOH

NH HN H'P03 O COOH
aNH H3P03/conc. HC1 H PO

/\ HN HCHO, L~
O N O
r__~N N
COOH

~ HZP03 bH2po3 COOH -N-Phenyl N-(1-chloro 3-carboxvnhenvl)amine 9:
To a stirred solution of 20.0 g (0.145 mole) of 2-nitroaniline 1, 28.0 g(0.146 mole) of 2,3-dichlorobenzoic acid in 200 mL dry dimethyl sulfoxide, 20.0 g (0.19 mole) of anhydrous sodium carbonate is added. The reaction mixture is heated at 110 C for 5 hours under nitrogen atmosphere. The dimethyl sulfoxide solvent from the reaction mixture is removed under high vacuur,i and dried. The crude product is extracted three times each time with 100 mL methylene chloride by partitioning into water. The combined methylene chloride layer is dried over anhydrous sodium sulfate and filtered.
Solvent from the filtrate is removed under reduced pressure and dried. The crude residue is chromatographed on a silica gel 60 column (230-400 mesh) using 25% ethyl acetate in hexane as an elution solvent. The fractions containing the desired product are combined and the solvent removed under reduced pressure to yield 20.0 g(470) of N-phenyl N-(1-chloro 3-carboxyphenvl) amine 9.
N,N'-Bis(2-dini=roohenvl)-2,3-diamincbenzoic acid 10:
10.0 g (0.034 mole) of N-phenyl N-(1-chloro 3-carboxyphenyl) amine, 9 ar.d 5.20 g (0.038 mole) of 2-nitro aniline 1 are dissolved in 200 mL anhydrous dimethylformamide (DMF) solvent. To the magnetically stirred solution, copper powder 0.22 g(0.0035 mole) and copper iodide 0.65 g(0.0034 mole) and sodium carbonate 3.62 g (0.034 mole) are added and heated under reflux in an oil bath. A slow stream of nitrogen gas is maintained throughout the course of the reaction. The reaction mixture is heated for 24 hours. Solvent from the reaction mixture is removed under high vacuum and dried. The crude residue is dissolved in water and extracted three times each time with 150 mL methylene chloride. The combined methylene chloride extracts is washed with brine and water.
The organic layer is dried over anhydrous sodium sulfate and filtered. Solvent from the filtrate is removed under reduced pressure and dried. The crude residue is purified by silica gel column chromatography using 25% ethyl acetate in hexane as an elution solvent. Fractions containing the desired compound are pooled and the solvent removed under reduced pressure to yield 8.0 g(60b) of desired compound 10.
N,N'-Bis(2-diaminoohenvl)-2,3-diaminobenzoic acid 11:
2.0 g (0.00.5 mole) of N,N'-Bis(2-dinitrophenyl)-2,3-diaminobenzoic acid 10 is taken into a hydrogenation pressure bottle. 200 mL of 2% glacial acetic acid in absolute ethanol is added. To the suspension, 0.4 g of 10% palladium on activated cazbon is added. The reaction mixture is catalytically reduced under hydrogen atmosphere using a parr hydrogenation apparatus at 60 PS~- for 6 hours. The solutior.
is filtered and the solvent removed under reduced pressure and dried. The crude residue is used as an acetate salt without further purification for the subsequent reactions. The yield of the product is 50-60%.
2, 3, 8, 9-dinhenvlenv'_ 5, 6, 11, 12-bis ort::o carboxvdinhenvienvi-Wl) 9M/43b-/2f PCT/US98/05858 1 ,4,7,10-tetraazadodecane 12:
1.0 g (0.002 mole) of N,N'-Bis(2-diam_noehenyl)-2,3-diaminobenzcic acid diacetate 11 and 0.47 (0.002 mole) of 2,3-dichloro benzoic acid are dissolved in 100 mL of anhydrous 5 dimethylformamide solvent. To a magnetically stirred -solution, copper powder 0.160 (0.1002 mole) and copper iodide 0.38 g (0.002 mole) and sodium carbonate 1.0 g (0.01 mole) are' added and heated under reflux in an oil bath. A slow stream of nitrogen is maintained throughout the course of the 10 reaction. The reaction mixture is heated at 115 to 1200C for 36 hours. Solvent from the reacticn mixture is removed under reduced pressure and dried. The crude residue is purified by reverse phase HPLC using aqueous acetonitrile containing acetic acid as a mobile phase. The fractions cor.ta-7r::ng the 15 desired product are combined and the solvent removed under reduced pressure to give 50% of the desired compound, 2,3,9,9-diphenylenyl 5,6,11,12-bis ortho carboxy-dipheny?enyl-1,4,7,10-tetraazadodecane 12.
2 3 , 8 , 9,-d.inhenvlenvl 5, 6, 11, 12-bi s ortho carboxvd? ohenviAr.vl-20 1 4,7,10-te*_raazacvclododecane N,N',N",N"'-tetraacetic acid 13:
To a stirred suspension of 10.0 g (0.022 mole) 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane 12 in 200 mL distilled water, 30.8 g (0.22 mole) of bromoacetic acid is added and magnetically 25 stirred. The pH of the solution is adjusted to 10.0 with 2.0 N scdium hydroxide and the reaction mixture is heated in an oil bath at 45 C for 20 hours. The pH of the reaction solution is maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide during the entire course of reaction. The progress 30 of the reaction is monitored by HPLC using PRP-X100anion exchange column and small amounts of bromoacetic acid (i.e., 100 to 200 mg) are added to the reaction mixture to drive the reaction to completion. The reaction mixture is diluted with sterile water to a 2 liter volume and the pH is adjusted to 35 6.8 with 6.0 N hydrochloric acid. The conductivity for this * 'It8demMk solution is 4.89 ms/cm. It is further diluted to 4 liters with sterile water and the pH is adjusted to 8.2 with 2.0 N
sodium hydroxide. The measured conductivity is 2.89 ms/cm.
This solution is loaded on 5 x 60 cm column with 900 mL bed volume of AGCR) 1-X2 (acetate form) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 liter water, 0.5 liter 0.02 N ammonium acetate pH 7.18 and 4 liter water final eluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water and solvent B (1.50 M acetic acid) of the gradient system is gradually increased. Fractions containing the product are pooled and solvent evaporated and dried under high vacuum to give 5.6 g (40%) of pure compound 13.
2. 3, 8, 9-dinhenylenvl 51 6, 11, 12-bis ortho carboxvd'_ohAnvlen,: i-1, 4, 7, 10-*_etraazacvclododecane N, N', N", N"'-tetramethilene ghosohonic acid 14:
25.0 g (0.31 mole) o'L' phosphorous acid and 20 mL of degassed water are taken into a 3 neck round bcttom flask equipped with a dropping funnel, a thermometer, and a magnetic stir bar. The flask is flushed with nitrogen gas and a slow stream of nitrogen is maintained in the reaction flask.
Dissolution of the phosphorous acid is achieved upon stirr=ng.
15.0 mL of concentrated hydrochloric acid is added to the reaction mixture and the stirring continued. The dropping funnel is charged with 20.0 g (0.044 mole) of 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl 1,4,7,10-tetraazacyclododecane, 12 dissolved in 25 mL water. The cyclic tetrarnine solution from the dropping funnel is added dropwise to the stirred acidic solution under nitrogen atmosphere. After completion of addition, the reaction mixture is heated under reflux using an oil bath for at leas--1.0 hour. The dropping funnel is charged with formaldehyde 27.2 g (0.938 mole) of a 37% aqueous solution and is added to the reaction mixture dropwise over a 2 to 3 hour time interval. The reaction mixture is continued heating under reflux throughout the entire formaldehyde solution addition period. After completion of all of the formaldehyde solution, the reaction mixture is continuously stirred under reflux for an additional 3 to 4 hours. The reaction solution is then allowed to cool and the product, 2,3,8,9-diphenylenyl-1,4,7,10-bis ortho- carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane N,N',N",N"'-tetramethylene phosphonic acid 14 is isolated from the reaction mixture and purified by ion exchange resin chromatography in 40-50% yield.

Example IV
N,N'-Bis(2-diaminophenyl)-1,3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride 15 conjugated with Annexin V

N N Ac.2O

N rJ rN
J

N N r-Annexin V
pH 7-10 25 C - 37~C
0o 0 0 0 1.5 CO~H Co~H
~ r"*~-~ J
N N
. I ;
rN) rN) i 0 C02'rI CO2H CO2H
NH

I-Annexin V
lfi N,N'-Bis (2-diaminonhenvl)-1, 3-oronane N,N'-diacetic acid 2, 2'-tetraacetic acid dianhvdride 15:
10.0 g (0.018 mole) of N,N'-Bis(2-diaminophenyl)-1,3-propanediamino hexaacetic acid 4 is placed in a 500 mL round bottom flask. To the flask is added 200 mL of acetic pCT/US98/05858 anhydride. The reaction mixture is stirred magnetically and heated under reflux for 48 hours. Solvent from the reaction-mixture is removed under high vacuum and dried. The crude residue is purified by sublimation to yield 6.0 g (64%) of_ N, N'-Bis (2-diamincphenyl) -1, 3-propane N,N'-diacetic acid 2, 2'-tetraacetic acid dianhydride 15.
r-Annexin V conjuQation of N,N'-BisJ2-diaminophenvl)-1,3-prooane N,N'-diacetic acid 2.2'-tetraacetic acid dianhvdride 16:
N, N'-Bis ( 2-diaminophenyl )-1, 3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride 15 precursor is offered to r-Annexin V in molar ratios of 300:1, 150:1, 75:1, 25:1, 10:1 and 5:1. Typically for a molar offering of 75:1 dianhvdride to r-Annexin V ratio, 100 ul c-6- dimethy'_ su-1foxide or DMF
solvent containing 7.74 mg of N, ligand dianhydride is added dropwise with sti==ing to 2 mL of bu.fer with 25 mM HEPES ((N-[2-hydroxyethyl]pi-perazine-N'-[2-ethanesulfonic acid])), 150 mM sodium chloride, pH 8.0 containing 7.2 mg of r-Annexin V.
The reaction mixture is stirred for 2 hours at 25. C - 37 C
followed by purification by PD-10size exclusion chromatography equilibrated in PBS. The final product of the conjugate is exhaustively dialyzed in PBS.

TrademA&

Example V
Tc99ni radiolabeled N, N'-Bis (2-diaminophenyl )-1, 3-propane N, N'-diacetic acid 2,2'-tetraacetic acid dianhydride 15 C02H cOZH

J 99mTc-gluconate (OR) other N
99mTc-exchange agents rN) rN) 25 C- 37 -C, 15' -3C' 10 CO2H CO,H CO2H

NH
I-Annexin V
ls NON c "~
a N N
r ~ r I
i0 CO2H CO,H COZH
NH

i-Annexin V
]I

Example VI
Y90-labeled N, N'-Bis (2-diaminophenyl) -1, 3-propane diaminohexacetic acid 4 and N,N'-Bis(2-diaminophenyl)-1,3-propane-diamino hexamethylene phosphonic acid 5 COOH COOH

90 YC13 in 0.5 M N;Ha OAc N N
pH 5.0 N~ rN~ 25 ' C- 37 J C, 15' - 60' CO2H CO,ii CO,H CO,H

N N
; ~1 \ 90y NO \\N

C02H Co:H

1$

H, PO3 H., P03 F--~ 90 N N YC13 in 0.5 M H,N"O"Ac pH 5.0 N) rN~ 25 C - 37 D r C, 15' - 60' H,P03 H,PO3 HZP03 H,P03 ~

HO-,,II IP/0H
P\

r --1 N N
~-, ~90Y

/00I-. P

HO~ II oI ~0H

].~
9=~c-radiolabeiina procedure for N, liaand-r-Annexin V
con;uaate 16:
METHOD A: Stannous gluconate kits are prepared containing S.0 mg sodium gluconate 100 micrograms stannous chloride, 1.0 mg (1 mg/ml) of N4 ligand-r-Annexin V conjugate 16, and 0.1 to 1.0 mg of lactose. The pH is maintained between 5 and 7 using pCT/US98/05858 hydrochloric acid, acetic acid or sodium hyciroxide. To the stannous g'uconate kit is added 1.0 mL sodium pert=chnetate (99mTc0'a) with a specifi c activity of 50 mCi/mL. The vial is thoroughly m=xed and incubated at 25 C - 37 C for 15' - 30'.
The percent formation of radiolabeled conjugate, remaining Tc04, and hydrolyzed reduced technetium is determined by ITLC
in 12% TCA as developing solvent.
METHCD B: Stannous tartrate kits are prepared in an evacuator vial under nitrogen to contain 0.5 mL of disodium tartrate (10 mg/mL) and 0.1 mL stannous chloride (1.0 mg/mL in ethanol). The pH of the solution is kept between 5 and 7, preferably 6Ø To this stannous tartrate solution is added 1.0 mL of sod_um pertechnetate at a spec:fic concentration of 50 mCi/mL. The react4Lon mixture is allowed to stand at room temperature. In an evacuated vial, 200 /cl of sodium phosphate (0.5 M, pH 8.0 or 10.0) and 1.0 mL of N,N'-Bis (2-diaminophenyl)-1,3-propanediamino hexaacetic acid, 4 (1.0 mg/mL) are added successively. Then Tc-99m-tarzrate (50 mCi) is added, and the vial is incubated at 25 C - 37 C for 15' -30'. The percent formation of radiolabeled N4 ligand, remaining Tc04, and hydrolyzed reduced technetium is determined by ITLC in various solvents as developing solvent systems.
90Y radiolabelinq of compound 4 (18):
To carrier-free 0.6 mCi Y-90 C13 (10 /.cl, 50 mM HC1, NEN
Dupont), 0.18 mg of compound 4 in 450 l of 2.0 M NH4OAc, pH
5.0, is added and the reaction mixture is allowed to proceed for 30 minutes at 80 C. The percent of 90Y radiolabeling monitored by gradient HPLC system equipped with a radiometric detector is greater than 99%.
90Y radiolabelinQ of comDound 5(19) :
To carrier free 0.6 mCi Y-90 C13 (10 41, 50 mM HCl, NEN
Dupont), 18 mg of compound 5 in 450 ul of 2.0 M ammonium acetate, pH 7.0, is added and the reaction mixture is allowed to proceed for 30 minutes at 80 C. The percent of CY

radiolabeling as monitored by a gradient HPLC system equipped with a radiometric detection is greater than 99%.

Example VII
4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexaacetic acid 23 and 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylene phosphonic acid 24 NH2 ~ I I /DMSO, Na2CO3 s "C
NOZ ~ - 110'C - 115.

NH HN
Pd/c (10%) S S
\ EtOH/HOAC, H, N0~ 02N

BrCHC00H/pH 10.0 NH, HzN

COOH COOH

N N
S S
N JJ rN
J
COOH COOH COOH COOH

H,PC3 H,P03 NH ::c HP03, HCHHO, NHZ 22 rN) rNJ

H,PO3 H,PO3 H2P03 H2PO3 4-N,N'-Bis (3-dintirothioohenvl)-1.3-ororwl diamine 21:
To a stirred solution of 25.0 g (0.174 mole 3-nitro 4-5 aminothiophene and 10.2 g (0.034 mole) of 1,3-diiodopropane in 200 mL of dry dimethyl sulfoxide, 18.3 g(0.i72 mole) oi sodium carbonate is added and heated at 110 C - 115 C for 12 hours. Solvent from the reaction mixture is removed under high vacuum and dried. The crude residue is purified by 10 silica gel column chromatography using 30% ethyl acetate in hexane as an elution solvent. Fractions containing the product are combined and solvent removed under reduced pressure to yield 8.0 g (14%) of compound 21.

4-N,y'-Bis(3-d;aminothicohenyl)-1 3-croovldi3m;t~e 22:
5.0 g(0.015 mole) of 4-N,N'-3is(3-dinit=ot':4_ochenyl)-.
1,3-propyldiamine 2: is taken into a hydroge::at_cn bottle.
250 mL of 2% g?acial acetic acid in absolute etzanol is added.
To the suspension, 0.5 g of 10% palladium on activated carbon is added. The reaction mixture is catalytically reduced under hydrogen atmosphere at 60 PSI for 4-6 hours in a parr hydrogenation apparatus. The solution is filtered and the solvent removed under reduced pressure and dried. The crude residue is taken into a saturated sodium bicarbona*_e solution and the free amine is extracted into methylene chloride three times each time with 150 mL volume. The combined organic layer is dried over anhydrous sodium sulfate a:.c filtered.
Solvent from the filtrate is remcved under reduced pressure and dried to yield crude residue. The crude product is purified by silica gel column chromatography using 50% ethyl acetate in hexane as an elution solvent. Fractions containing the desired product are combined, solvent removed under reduced pressure and dried to yieid 3.50 g (75%) of compound 22.
4-N,N'-Bis(3-diaminothiophenvl)-1,3-r)ropanediamino hexaacetic acid 23:
To a stirred suspension of 5.0 g (0.016 mole) of 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamine 2,7.. in 100 m:. of distilled water, 22.6 g (0.163 mole) of bromoacetic acid is added and magnetically stirred. The pH of the so-uticn is adjusted to 10.0 with 2.0 N sodium hydroxide and the reaction mixture is heated :n an oil bath at 45 C for 16 hours. The pH
is maintained between 9.75 and 10.0 with 5.0 N sod'-um hydroxide during the entire course of reaction. Progress of the reaction is monitored by HPLC using PRP-X100anion exchange column and small amounts of bromoacetic acid is added to the reaction mixture to drive the reaction to completion.
The reaction mixture is diluted with sterile water to 2 liter volume and the pH is adjusted to 6.8 with 6.0 N hydrochloric * Tradenv&

acid. The conductivity for this solution is 4.89 Ms/cm. It is further diluted to 4 liters with sterile water and the pH
is adjusted to 8.2 with 2.0 N sodium hydroxide. The measured conductivity is 2.89 Ms/cm. This solution is loaded on 5 x 60 cm column with 900 mL bed volume of AGO 1-X2 (acetate form) resin which is prewashed with 1 liter 1.50 M acetic acid, 1.5 liter water, 0.5 liter 0.02 M ammonium acetate pH 7.18 and 4 liter water final eluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water and gradually increased the solvent B (1.50 M acetic acid) of the gradient system.
Fractions containing the product are pooled, solvent evaporated and dried under high vacuum to give 7.50 g (81%) of compound 21.
4-N.N'-Bis(3-diaminothioohenvl)1.3-oroQanediamino hexamethvlene ohosnhonic acid Zg:
25.0 g (0.31 mole) of phosphorous acid and 25 mL of degassed water are taken into a 3 neck round bottom flask equipped with a dropping funnel, a thermometer and a magnetic stirring bar. The flask is flushed with nitrogen gas and a slow stream of nitrogen is maintained in the flask.
dissolution of the phosphorous acid is achieved upon stirring.
mL of concentrated hydrochloric acid is added to the reaction mixture and stirring continued. The dropping funnel is charged with 20.0 g (0.065 mole) of 4-N,N'-Bis(3-25 diaminothiopheynl)-1,3-propanediamine dissolved in 25 mL of water. The amine solution from the dropping funnel is added dropwise to the magnetically stirred acidic solution under ntirogen atmosphere. After completion of addition the reaction mixture is heated under reflux using an oil bath for 30 at least 1.0 hour. Then the dropping funnel is charged with formaldehyde 22.0 g (0.73 mole) of a 37% aqueous solution and is added to the reaction mixture dropwise over a 2-3 hour time interval. The reaction mixture is continued heating under reflux throughout the entire formaldehyde solution addition period. After completion of all of the formaldehyde solution, the reaction mixture is continued stirring under reflux for an additional 4-6 hours. The reaction mixture is then allowed to cool and the product 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylene phosphonic acid 2,4, is isolated from the reaction mixture and purified by ion exchange resin chromatography.

Example VIII
2,3,9,10-[2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N,N',N",N"'-tetraacetic acid 2& and 2,3,9,10-[2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N, N', N", N"'-tetramethylene phosphonic acid 27 NH HN
I I DMSO, Na2CO3 S g _ NHZ H2N L , 110'C - 115,C
?.2 NH HN
a BrCH2C00H/pH 10.0 S g NH H

COOH COOH

N N
S\ S
/ \
N

rui COOH COOH
NH HN
C H3P03, conc. HCl S g HCHO, NH H

N N

S
/
N

27_ 2,3,9,10-f(2,3- 9,10-c')-ditnioohenvll-1,4 8, 1 -tetraazacvclo t=t=adecane 25: A stirred solution of 10.0 g (0.037 mole) of 4-N,N'-Bis(3-diaminothioohenyl)-1,3-propanediamine 22, 2.0 g (0.007 5 mole) of 1,3-diiodopropane and 5.70 g (0.068 mole) of sodium bicarbonate in 100 mL dry dimethyl sulfoxide is heated at 115 C for 4 hours under nitrogen atmosphere. The dimethyl sulfoxide solvent is removed under high vacuum and dried. The crude product is extracted three times each time with 100 mL
10 methylene chloride by partitioning with water. The combined znethylene chloride layer is washed with brine and water. The organic layer is dried over anhydrous sodium sulfate and filtered. Solvent from the filtrate is removed under reduced pressure to yie'_d crude residue. The crude residue is 15 purified by flash chromatography on a silica ge? column using 25% ethyl acetate in hexane as an e?ution solvent. The fractions containing the product are combined and the selvent removed under reduced pressure and dried to yield 4.0 g (35%) of compound 25.
20 2,3,9.10-f(2,3-C, 9,10-C)-dithiccher.v?l-1,4.8,11-terraacacvclo tetradecane N, N', N", N'-tetraac jic acid 26:
To a stirred suspension of 1_0.0 g(C.033 mole) of compound 25 in 200 ml, of dist:::ed water, 40.0 y(0.288 mole) of bromoacetic acid is added. The reaction mixture is stirred 25 magnetically at room temperature. The pti of the solution is adjusted to 10.0 with 2.0 N sod':um hvdrox.de and the reaction mixture is heated in an oil bath at 45 C for 2G hours. The'pH
is maintained between 9.75 and 10.0 with 5.0 N scdium hydroxide during the entire course of reaction. Progress of 30 the reaction is monitored by HPLC using PRP-X100*anion exchange column and small amounts of bromoacetic acid (i.'e., 100-200 mg) are added to the reaction mixture to drive the reaction to comt)letion.. The reaction mixture is diluted with sterile water to 2 liter volume and the pH is adjusted to'6.8 35 with 6.0 N hydroch?oric acid. The conductivity for this * TrademUk solution is 4.89 Ms/c:n. It is furthe= diluted to 4 liters with sterile water and the pH is adjusted to 8.2 with 2.0 N
sodium hydroxide. The measured conductivity is 2.89 Ms/cm.
This solution is i.oaded on 5 x 60 cm column with 900 mL bed volume of AG R 1-X2 (acetate form) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 liter water, 0.5 liter 0.02 M ammonium acetate pH 7.18 and 4 liter water final eluent pH 4.28 by FPTC at 40 mL/min. The column is eluted with water and gradually increased the solvent B (1.50 M acetic acid) of the gradient system. Fractions containing the product are pooled and solvent evaporated and dried under high vacuum to give 8.0 g (46%) of compound 26.
2 3 910- f 12 3-r' te*_radecane 0 1 11os:,ho~; c acid 5.0 g(0.061 mole) of phosphorous acid and 10 mL of degassed water are taken into a 3 neck round botzom flask equipped with a dropping funnel, a thermometer and a stir bar.
The flask is flushed with nitrogen gas and a slow stream of nitrogen is maintained in the flask. Dissoluticn of the phosphorous acid is achieved upon stirring. 10.0 mL of concentrated hydrochloric acid is added to the reaction mixture and the stirring continued. The dropping funnel is charged with 4.0 g(0.C13 mole) of 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenylJ-1,4,8,1:-tetraazacyclo tetradecane 25 dissolved in 15 mL water. The cyc!ic amine solution from the dropping funnel is added dropwise to the stirred acidic sol::tion under nitrogen atmosphere. Az-ter completion of additicn, the reaction mixture is heated under reflu:{ using an oil bath for at least 1.0 hour. Then the dropping funnel is charged witr.
formaldehyde 5.0 g (0.172 mole) of a 37% aqueous solution and is added to the reaction mixture dropwise over a 2 to 3 hour time period. The reaction mixture is continued heating under reflux throughout the entire formaldehyde solution addition.
After complet?on o' all of the formaldehyde solution, the reaction mixture is continuously stirred under reflux for an additional 3 to 4 hours. The reaction mixture is then allowed to cool and the product 2, 3, 9, 10- [(2, 3-C; 9, 10-C') -dithiophenyl]-1,4,8,11-tetraazacyclotetradecane N,N',N",Nl"-tetramethylene-phosphonic acid 27 is isolated from the reaction mixture and purified by ion exchange chromatography in 25% yield.

Example IX
4 -N, N'-Bis (3-diaminothiophenyl) 1, 3 -propanedi amino hexamethylene phosphonic acid 24 and 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N,N',N",N"'-tetramethylene phosphonic acid 27 is Y90 labeled H,PO3 HZP03 / 90 + -N N YC13 in 0.5 M H4N 0 Ac a pH 5.0 S g rN) N) 25 " C - 37 " C, 15' - 60' H2P03 HZP03 H,P03 H2PO3 ll,oH
S 9oY~
N
N N
~P/o % PJ

HOOI j0 \0 H2P03 2a 90YC13 in 0.5 M H4N'0 AC
N N
pH 5.0 S S
\ C

/ r ~jj 25 C - 37 C, 15'- 60' 2?

HO-"11 11,OH
P
S a:~ 90Y/
~ s N/ ~
P/0 O"' 90Y-radiolabeling of compound 24 (28):
To carrier free 0.6 mCi Y-90 C13 (10 l, 50 mM HC1, NEN
Dupont), 0.18 mg of compound 24 in 450 l of 2.0 M ammonium acetate, pH 5.0, is added and the reaction mixture is allowed to proceed for 30 minutes at 80 C. The percent of 90Y-radiolabeling monitored by a gradient HPLC system equipped with a radiometric detector is greater than 99%.
90Y-radiolabeling of comnound 2-7 (29) :
To carrier free 0.6 mCi Y-90 C13 (10 l, 50 mM HC1, NEN
Dupont), 180 mg of compound 27 in 450 l of 2.0 M ammonium acetate, pH 7.0, is added and the reaction mixture is allowed to proceed for 30 minutes at 80 C. The percent of 90Y-radiolabeling monitored by gradient HPLC system equipped with '15 a radiometric detection is greater than 99%.

Example X
Biocytir, conjugated on Tc99in radiolabeled N, N'-Bis ( 2-diaminophenyl)-1,3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride 15 COZH COZH
N N ) Biocytin pH 7-10; 25 C - 37 " C
2 hours O O o 0 O O
1~

COZH )O:H

N N
~ --~
i 0 COZH CO2H CO2H

R'-N Biocytin ~ R ~ H, CH3 HN
/NH
R H, CH3 -~, H S

Biocvtin coniuQatior. of N, N'-Bis (2-di aminoohPnyi) -I '-b-opane N,N'-diace_ic ac'd 2,2'-retraacetic acid dianhvdride 15 (10) Typically to a stirred beaker of 25.0 mL of 0.20 M
borate, pH 8.0, is added in sequential order 1.25 mL of dimethyl'ormamide containing 129 mg (0.25 m moles) of N,N'-Bis(2-diaminophenyl)-1,3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride chelate followed by 1.25 mL of DMF containing 9.3 mg (0.025 m moles) of biocytin free base.
After incubation at 25 C for 2 hours with stirring, the desired product is separated from the reactants and side products by preparative reverse phase C-18 chromatography, such as the DYNAi'~AXO-60A (supplied by Rainin Instrument Co.).
Alternatively in a stirred beaker of 25 mZ. of dimethylformamide is added 1.25 mL DMF containing 121 ;n5 (0.25 m moles) of N,-dianhydr=de chelate 15, 1.25 mL of DMF
containing 9.3 mg (0.025 m moles) of biocytin free base and 1.25 mL of DMF containing 0.025 m moles of diisopropyl ethylamine. The reaction mixture is stirred at room temperature overnight. The desired product is purified by reverse phase C-18 chromatography.
The in vitro binding efficacy of the biocytin derivatized N4 chelate to avidin or streptavidin is assessed using the standard HABA ([2(4'hydroxy-azobenzene)benzoic acid]dye) UV/VZS spectrophotometric assay of Green et al. (Biochern. J., 94:23c-24c, 1965). The radiolabeling with radioactive metals 90Y and lllin is perFor:ned in 2.0 M acetate buffer, pH 5.0 as described earlier in labeling the N, tetramethylene phosphonate ligands.

Example XI
N,N'-Bis(2,disulfidyl-4-ethoxycarbonylpnenyl)-1,3-propyldiamine D DMSO/A
0 jC + I I 110C
Et0 3.Q

NH HN
NH4 SC:I/HOAc Br2/HOAc ia /C C~
Et0 ~ OEt N 50% KOH
NHHN A, 2 - 3 Days /C S S C~
Et0 OEt NH HN EtOH/HC1 HOZC S S COZH
NH HN BrCH,CO,H
~ ~, pH 10.0 ~ ~
EtOzC S S CO,Et aA
COZH COZH
Tc-gluconate j or N N other exchange agents ~- l-.
~ ~ pH 5-7, 25 C- 100 C
HO,C S S CO2H

N\ II N
-, Tc ~~
Ho2C S s COH
4,4-Diethoxvcarbonvlproovl-1,3-diani'_ine A stirred solution of 2.065 g(1.25 mole~ ethyl-4-amizc benzoate 3, 14.35 mL (0.125 mole) 1,3-diidopropane and 10.5 g (0.125 mole) sodium bicarbonate in 500 mL dry dimethyl sulfoxide was heated at 110 C for 3 hours under nitrogen.
Upon cooling, the mixture was poured into 2 L of ice water with stirring and the resulting precipitate collected by filtration. The precipitate was then washed with glacial acetic acid (14 x 75 mL) until all of the starting ethyl-4-aminobenzoate had been removed. After drying in vacuo, the product, 31, thus obtained was used in the next step without further purification.

1,3-di(2-imino-6-ethoxvca_bonvlbenzthia_olv'-3-)erooane Ammonium thiocyanate (16.5 g, 0.211, mole) was added to a magnetically stirred suspension of 4,4-diethoxycar5onylpr~-,pyl-1,3-dianiline (10.Og, 0.027 mole) (prepared as described above) in 1500 mL glacial acetic acid. A solution of bromine (34.6 g, 0.216 mole) in 100 mL glacial acetic acid was then added dropwise to the suspension with stirring at room temperature. After stirring the reaction mixture overnighz at room temperature, the dihydrobromide salt of the cruae product was collected by filtration and dried. The product, 33, was isolated by dissolving the crude product in hot water, adjusting to basic pH with the addition of satsrated sodium bicarbonate solution, collecting the precipitate by filtration, and drying in vacuo.
N,N'-Bis(2-disulfidvl-4-carbonvlphenyl) -l,3-orooyldiamine 33:
Solid potassium hydroxide (20.0 g, 0.357 mole) was added to a suspension of the (1.0 g, 0.002 mole) IZ in 40 ml, distilled water, and the resulting mixture was heated at 120 C
for 12 hours. Complete dissolution occurred after 1 hour.
The reaction mixture was then cooled in an ice bath and the pH
was adjusted to 5.0 with 5.0 N ace*_ic acid. The aqueous solution was then extrac:.ed with three 100 m:, pcrticns of ethyl acetate. The combized ethyl acetate exzr3cts were dried over anhydrous sodium sulfate and the drying agent was filtered. Removal of solvent yielded the product 3.
N,N'-Bis(2-disulfidvl-4-ethoxvcarbonvlohenyl)-1,3-groDvldiamine 34:
A magnetically stirred suspension of 33 (0.5 g, 0.0013 mole) in 200 mL absolute ethyl alcohol was saturated with dry hydrogen chloride gas. The reaction mixture was then heated under reflux for 3 days. Upon cooling, the solvent was removed under reduced pressure, to yield the product, 34, as its dihydrochloride salt. A solution of the salt in 100 mL
distilled water was adjusted to pH 8.5 to 9.0 with 0.2 M
sodium bicarbonate solution and the aqueous solution was extracted with three 100 mi portion methylene chloride. The combined methylene chloride extracts were dried over anhydrous sodium sulfate and the drying agent filtered. Removal of the solvent under reduced pressure gave the crude product 34 which was isolated and purified by flash chromatography using silica gel and eluting with methylene chloride and ethyl acetate.

N, N'-3is (2-disu' =idvl-4-carboxvphenvl)-1, 3-oroovldiamine N,N'-diacetic acid ' ~ =
To a stirred suspension of 10.0 g (0.023 mole) of 34 in 200 mL distilled water, 40.0 g (0.288 mole) of bromoacetic acid is added. The reaction mixture is stirred magnetically at room temperature..The pH of the solution is adjusted to 10.0 with 2.0 N sodium hydroxide and the reaction mixture is heated in an oil bath at 45 C for 16 hours. The pH is maintained between 9.75 and 10.0 with 5.0 N sodium hydroxide during the entire course of reaction. The progress of the reaction is monitored by HPLC using PRP-X100anion exchange column and small amounts of bromoacetic acid is added to the reaction mixture to drive the reaction to comple:.ion. The reaction mxiture is diluted with sterile water to 2 liter volume and the pH is adjusted to 6.8 with 6.0 N hydroc'r.loric acid. The conductivity for this solution is 4.89 ms/cm. It is further diluted to 4 liters with sterile water and the pH .
is adjusted to 8.2 with 2.0 N sodium hydroxide. The measured conductivity is 2.89 ms/cm. This solution is loaded on 5 x 60 column with 900 mL bed volume of AG 1-X2 (acetate form) resin which is prewashed with 1 liter 1.5 M acetic acid, 1.5 liter water, 0.5 liter 0.02 N am.~aonium acetate pH 7.18 and 4 liter water final eluent pH 4.28 by FPLC at 40 mL/min. The column is eluted with water and so;vent B (1.50 M acetic acid) of the gradient system is gradua:ly increased. Fractions containing the product are pooled and solvent evaporated and dried under high vacuum to give 7.10 g (40%) of compound Tc-99m radiolabelina cf N,N'-Bis(2-disulfidv1-4-carboxvohenvl)-1.3-oroovld_amine N.N'-diacetic acid 36:
A solution of 0.6 mL of 170 g/mL N,Ng-bis(2-disu'_f'-dyl-4-ethoxylcarbonylphenyl)-1,3-propyldiamine N,N'-diacetic acid in either acetonitrile or isopropanol is added to 1.1 mL of Tc-99m gluconate (prepared from 0.12 mg stannous chloride dihydrate, 5.0 mg;sodium gluconate at pH 6.1 - 6.3, and 100 *'rrademedC

= =

mCi/mL of Tc-99m pert=chnetate). The resulting mixture is incubated either at room temperature for 15-30 minutes or heated at 75 C for 2-5 minutes followed by cooling with an ice bath. The crude reaction mixture is then diluted with 3 mL
water and purified by reverse phase chromatography. The crude product is loaded onto a pre-conditioned C-18 sample preparation cartridge (SPICE'a" cartridge supplied by Analtech) and eluted with 5 mL water followed by 10 mL 5% ethanol-saline, and 10 mL 10% ethanol saline, respectively. The Tc-' 99m chelate product is eluted with 10 mL 50% ethano?-saline.to give 75% radiochemical yield of the desired product. The radiochemical purity of the eluent is analyzed by reverse phase C-18 isocratic liquid chromatography using 50% ethanol-saline as the mcbile phase at a flow rate of 0.8 mL per minute.

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been desc-ribed herein for the purpose of illustration, various modifications may be made without deviating from the spirit and scope of the invention.

.- ,

Claims (35)

What is claimed is:
1. ~A compound of the formula:

wherein:

n = 1;
R1 and R2 are independently selected from hydrogen, =O, with the proviso that both are not =O, -(CH2)m-Z where m is 0-10 and Z represents a conjugation group or targeting moiety, and -(CH2)m-W where m is 0-10 and W
represents a hydrolyzable group, or R1 and R2 are taken together to form a cyclic anhydride or a benzene ring;

R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m -Z or - (CH2)m-W;

R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z and -(CH2)m-W;
R6 and R7 are independently selected from hydrogen with the proviso that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m -Z, -(CH2)m-W and where Q represents a multivalent acid functionality group able to coordinate with metal ions, and p = 0 to 1; R12 and R13 are independently selected from hydrogen, hydroxyl, carboxyl, phosphoric, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals;

X, X', Y and Y' are independently selected from carbon, nitrogen, oxygen and sulfur to independently form 5 or 6 member aromatic rings wherein the remaining ring atoms are carbon;

A and A' are independently selected from sulfur and nitrogen, where sulfur may bear a hydrogen or a sulfur protecting group, or where A and A' are both sulfur, A and A' may be joined together by a bond; where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or R10 or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11 are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z, -(CH2)m-W and or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10 and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O, with the proviso that both are not =O, -(CH2)m-Z, and -(CH2)m-W, or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z or -(CH2)m-W; and the compound has at least one Z, W or Q.
2. ~A compound according to claim 1, wherein:

R1, and R2 are independently selected from. hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-Z where m is 0-10 and Z represents a conjugation group or targeting moiety, or R1 and R2 are taken together to form a cyclic anhydride or a benzene ring;
R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-Z;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-Z;

R6 and R7 are independently selected from hydrogen with the provision that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-Z or X, X', Y and Y' are independently selected from carbon, nitrogen and sulfur to form 5 or 6 member aromatic rings wherein the remaining ring atoms are carbon;

A and A' are independently selected from sulfur and nitrogen, where sulfur may bear a hydrogen or a sulfur protecting group, or where A and A' are both sulfur, A and A' may be joined together by a bond; where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or Rio or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11 are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z and or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10 and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-Z; or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-Z; and said compound has at least one Z or Q.
3. ~A compound according to claim 2, wherein n = 1; R1, R2, R3 are hydrogen; R4 and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are where p = 0, R12 and R13 are hydrogen, Q is a multivalent acid functionality capable of coordinating with metal ions; A and A' are both nitrogen, wherein A bears R8 or R10 or both, and A' bears R9 or R11 or both, wherein R8, R9, R10 and R11 are where Q is independently selected from a phosphonic acid and a carboxylic acid, p 0, and R12 and R13 are hydrogen; or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or R10 and may be joined to form T wherein n is 1, and R1', R2' and R3' are hydrogen.
4. ~A compound according to claim 2, wherein R1 and R2 are taken together to form a benzene ring; R4 and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R 12 and R13 are hydrogen; A and A' are both nitrogen and R10 and R11 are joined to form T, wherein n=0, R1' and R2' are taken together to form a benzene ring and R8 and R9 are wherein Q may be independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen.
5. ~A compound according to claim 2, wherein n = 1; R1, R2 and R3 are hydrogen; R4, and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen; A and A' are both nitrogen, R8, R9, R10 and are independently selected from -(CH2)m-Z, wherein m is 0 to 10 and Z is a targeting moiety, and wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen, with the proviso that said compound has at least one Z.
6. ~A compound according to claim 5, wherein Z is a targeting moiety selected from the group consisting of antibody fragments, biotin and annexin.
7. ~A compound according to claim 1, wherein:
R1 and R2 are independently selected from hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-W where m is 0-10 and W represents a hydrolyzable group, or R1 and R2 are taken together to form a cyclic anhydride or a benzene ring;
R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-W ;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-W;
R6 and R7 are independently selected from hydrogen with the proviso that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-W
and A and A' are independently selected from sulfur and nitrogen, where sulfur may bear a hydrogen or a sulfur protecting group, or where A and A' are both sulfur, A and A' may be joined together by a bond; where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or R10 or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11, are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-W and or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10 and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O
with the proviso that both are not =O, and -(CH2)m-W where m is 0-10 and W represents a hydrolyzable group, or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-W; and said compound has at least one W.
8. ~A compound according to claim 7, wherein n = 1; R1, R2 and R3 are hydrogen; R4 and R5 is independently selected from hydrogen and -(CH2)m-W;
R6 and R7 are wherein Q are independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen; A or A' may be independently selected from a sulfur containing a protecting group, and nitrogen, with the proviso that both A and A' are not sulfur; and when A or A' is nitrogen, R8 or R9 is -(CH2)m-W, wherein m is 1 to and W is a hydrolyzable group.
9. ~A compound of claim 8 wherein W is selected from the group consisting of ester, carbamate and nitrile.
10. ~A compound according to any one of claims 2 to 9, wherein X, X', Y and Y' are all carbon.
11. ~A compound selected from N,N'-Bis(2-diaminophenyl)-1,3-propyldiamino hexaacetic acid; 2,3,9,10-diphenylenyl- 1,4,8,11 -tetraazacyclo tetradecane-N,N',N",N"'-tetraacetic acid; 2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane-N,N',N",N"'-tetramethylene phosphonic acid; 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane N,N',N",N'''-tetraacetic acid; 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl- 1,4,7,10-tetraazacyclododecane N,N',N",N'''-tetramethylene phosphonic acid; N,N'-Bis(2-diaminophenyl)-1,3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride; 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexaacetic acid; 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylene phosphonic acid; 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N,N',N",N"'-tetraacetic acid; and 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N,N',N",N'''-tetramethylene phosphonic acid.
12. ~A complex comprising a compound according to any one of claims 1 to 11, with a radionuclide metal or an oxide or nitride thereof.
13. ~A complex according to claim 12, wherein the radionuclide is a radionuclide of technetium, copper, rhenium, lead, bismuth, ruthenium, rhodium, yttrium, samarium, indium, gold, gadolinium, holmium, lutetium, ytterbium or palladium.
14. ~A complex according to claim 13, wherein the radionuclide is a radionuclide of technetium, rhenium, indium, holmium or yttrium.
15. ~A complex according to claim 13, wherein the radionuclide is 64Cu, 67Cu, 90Y, 97Ru, 99mTe, 105Rh, 109Pd, 111ln, 153Sm, 159Gd, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 198Au, 199Au, 203Pb, 212Pb or 212Bi.
16. ~A complex according to claim 14, wherein the radionuclide is 99m Tc, 186Re, 188Re, 111ln, 166Ho or 90Y.
17. ~A complex according to any one of claims 12, 13, 14, 15 or 16 for use in a diagnostic or therapeutic method.
18. ~A complex according to any one of claims 12, 13, 14, 15 or 16 for use in the manufacture of a medicament.
19. ~A radionuclide metal chelate compound of the formula:

wherein:
M is a radionuclide metal or an oxide or a nitride thereof selected from technetium, copper, rhenium, lead, bismuth, ruthenium, rhodium, yttrium, samarium, indium, gold, gadolinium, holmium, lutetium, ytterbium or palladium;
n = 0 or 1;
R1 and R2 are independently selected from hydrogen, =O, with the proviso that both are not =O, -(CH2)m-Z where m is 0-10 and Z represents a conjugation group or targeting moiety, and -(CH2)m-W where m is 0-10 and W
represents a hydrolyzable group, or R1 and R2 are taken together to form a cyclic anhydride or a benzene ring;

R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m -Z or - (CH2)m W;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, - (CH2)m -Z and - (CH2)m -W;

R6 and R7 are independently selected from hydrogen with the proviso that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m -Z, -(CH2)m -W and where Q represents a multivalent acid functionality group able to coordinate with metal ions, and p = 0 to 1; R12 and R13 are independently selected from hydrogen, hydroxyl, carboxyl, phosphoric, and hydrocarbon radicals having from 1-10 carbon atoms, and physiologically acceptable salts of the acid radicals;

X, X', Y and Y' are independently selected from carbon, nitrogen, oxygen and sulfur to independently form 5 or 6 member aromatic rings wherein the remaining ring atoms are carbon;

A and A' are independently selected from sulfur and nitrogen, where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or R10 or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11 are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m -Z, -(CH2)m -W and or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10, and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O, with the proviso that both are not =O, -(CH2)m-Z, and -(CH2)m-W, or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z or -(CH2)m-W; and the compound has at least one Z, W or Q.
20. A compound according to claim 19, wherein:

R1, and R2 are independently selected from hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-Z where m is 0-10 and Z represents a conjugation group or targeting moiety, or R1 and R2 are taken together to form a cyclic anhydride or a benzene ring;

R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-Z;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-Z, R6 and R7 are independently selected from hydrogen with the provision that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-Z or X, X', Y and Y' are independently selected from carbon, nitrogen and sulfur to form 5 or 6 member aromatic rings wherein the remaining ring atoms are carbon;

A and A' are independently selected from sulfur and nitrogen, where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or R10 or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11 are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m-Z
and or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10 and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-Z; or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-Z; and said compound has at least one Z or Q.
21. A compound according to claim 20, wherein n = 1; R1, R2, R3 are hydrogen; R4 and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are where p = 0, R12 and R13 are hydrogen, Q is a multivalent acid functionality capable of coordinating with metal ions; A and A' are both nitrogen, wherein A bears R8 or R10 or both, and A' bears R9 or R11 or both, wherein R8, R9, R10 and R11 are where Q is independently selected from a phosphonic acid and a carboxylic acid, p 0, and R12 and R13 are hydrogen; or R8 and R10 may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or R10 and may be joined to form T wherein n is 1, and R1', R2' and R3' are hydrogen.
22. A compound according to claim 20, wherein n = 0; R, and R2 are taken together to form a benzene ring; R4 and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen; A and A' are both nitrogen and R10 and R11 are joined to form T, wherein n=0, R1' and R2' are taken together to form a benzene ring and R8 and R9 are wherein Q may be independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen.
23. A compound according to claim 20, wherein n = 1; R1, R2 and R3 are hydrogen; R4, and R5 are independently selected from hydrogen and -(CH2)m-Z; R6 and R7 are wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen; A and A' are both nitrogen, R8, R9, R10 and are independently selected from -(CH2)m-Z, wherein m is 0 to 10 and Z is a targeting moiety, and wherein Q is independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen, with the proviso that said compound has at least one Z.
24. A compound according to claim 23, wherein Z is a targeting moiety selected from the group consisting of antibody fragments, biotin and annexin.
25. A compound according to claim 19, wherein:
R, and R2 are independently selected from hydrogen, =O, with the proviso that both are not =O, and -(CH2)m-W where m is 0-10 and W represents a hydrolyzable group, or R, and R2 are taken together to form a cyclic anhydride or a benzene ring;
R3 is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro or -(CH2)m-W;
R4 and R5 are attached at one or more of the ring positions and are independently selected from hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-W;

R6 and R7 are independently selected from hydrogen with the proviso that both are not hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m,-W
and A and A' are independently selected from sulfur and nitrogen, where a nitrogen may bear a hydrogen; or where A or A' is nitrogen, A may bear R8 or R10 or both and A' may bear R9 or R11 or both, wherein R8, R9, R10 and R11, are independently selected from lower alkyl, alkoxy, halogen, hydroxyl, nitro, -(CH2)m W
and or R8 and RIO may be joined to form a cyclic anhydride or R9 and R11 may be joined to form a cyclic anhydride; or when A and A' are both nitrogen, R10 and R11 may be joined to form T, where T is and n is 0 to 1, and R1' and R2' are independently selected from hydrogen, =O
with the proviso that both are not =O, and -(CH2)m-W where m is 0-10 and W represents a hydrolyzable group, or R1' and R2' are taken together to form a cyclic anhydride or a benzene ring; and R3' is hydrogen, lower alkyl, alkoxy, halogen, hydroxyl, nitro and -(CH2)m-W; and said compound has at least one W.
26. A compound according to claim 25, wherein n= 1; R1, R2 and R3 are hydrogen; R4 and R5 is independently selected from hydrogen and -(CH2)m-W;
R6 and R7 are wherein Q are independently selected from a phosphonic acid and a carboxylic acid, p = 0, and R12 and R13 are hydrogen; A or A' may be independently selected from sulfur, and nitrogen, with the proviso that both A and A' are not sulfur; and when A or A' is nitrogen, R8 or R9 is -(CH2)m-W, wherein m is 1 to 10 and W is a hydrolyzable group.
27. A compound of claim 26 wherein W is selected from the group consisting of ester, carbamate and nitrile.
28. A compound according to any one of claims 20 to 27, wherein X, X', Y and Y' are all carbon.
29. A compound according to claim 19, wherein M is chelated to a compound selected from N,N'-Bis(2-diaminophenyl)-1,3-propyldiamino hexaacetic acid; 2,3,9,10-diphenylenyl-1,4,8,11-tetraazacyclo tetradecane-N,N',N",N"'-tetraacetic acid; 2,3,9, 1 0-diphenylenyl- 1,4,8, 11 -tetraazacyclo tetradecane-N,N',N",N"'-tetramethylene phosphonic acid; 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl- 1,4,7, 10-tetraazacyclododecane N,N',N ",N "'-tetraacetic acid; 2,3,8,9-diphenylenyl 5,6,11,12-bis ortho carboxydiphenylenyl-1,4,7,10-tetraazacyclododecane N,N',N",N"'-tetramethylene phosphonic acid; N,N'-Bis(2-diaminophenyl)-1,3-propane N,N'-diacetic acid 2,2'-tetraacetic acid dianhydride; 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexaacetic acid; 4-N,N'-Bis(3-diaminothiophenyl)-1,3-propanediamino hexamethylene phosphonic acid; 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N,N',N",N"'-tetraacetic acid; and 2,3,9,10-[(2,3-C, 9,10-C)-dithiophenyl]-1,4,8,11-tetraazacyclo tetradecane N, N', N", N"'-tetramethylene phosphonic acid.
30. A compound according to any one of claims 19-29, wherein the radionuclide is a radionuclide of technetium, rhenium, indium, holmium or yttrium.
31. A compound according to claim 30, wherein the radionuclide is 64Cu, 67Cu, 90Y, 97 Ru, 99m TC, 105Rh, 109Pd, 111In, 153Sm, 159Gd, 166Ho, 175Yb, 177Lu, 186Re, 188Re, 198Au, 199Au, 203Pb, 212Pb or 212Bi.
32. A compound according to claim 31, wherein the radionuclide is 99m TC, 186Re, 188Re, 111In, 1166Ho or 90Y.
33. A compound according to any one of claims 19-32 for use in a diagnostic or therapeutic method.
34. A compound according to any one of claims 19-32 for use as a radiodiagnostic or radiotherapeutic.
35. Use of a compound according to any one of claims 19-32 in the manufacture of a medicament for radiotherapy.
CA002284653A 1997-03-28 1998-03-26 Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy Expired - Fee Related CA2284653C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/829,533 US6005083A (en) 1997-03-28 1997-03-28 Bridged aromatic substituted amine ligands with donor atoms
US08/829,533 1997-03-28
PCT/US1998/005858 WO1998043678A2 (en) 1997-03-28 1998-03-26 Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy

Publications (2)

Publication Number Publication Date
CA2284653A1 CA2284653A1 (en) 1998-10-08
CA2284653C true CA2284653C (en) 2008-07-29

Family

ID=25254797

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002284653A Expired - Fee Related CA2284653C (en) 1997-03-28 1998-03-26 Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy

Country Status (7)

Country Link
US (7) US6005083A (en)
EP (2) EP1813607A3 (en)
JP (1) JP2002500629A (en)
CA (1) CA2284653C (en)
DE (1) DE69837038T2 (en)
ES (1) ES2281927T3 (en)
WO (1) WO1998043678A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms
BR9912053A (en) 1998-07-13 2001-04-03 Univ Texas Cancer treatment processes using therapeutic conjugates that bind to aminophospholipids
EP2311490A3 (en) 1998-07-13 2011-05-04 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US6239237B1 (en) * 1999-04-22 2001-05-29 Nova Chemicals (International) S.A. Group 8, 9 or 10 transition metal catalyst for olefin polymerization
AU5871000A (en) 1999-06-11 2001-01-02 Paul G. Abrams High dose radionuclide complexes for bone marrow suppression
US7094885B2 (en) 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6565828B2 (en) 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
BRPI0111220B8 (en) 2000-06-02 2021-07-27 Univ Texas drug conjugates with ethylenedicysteine (ec)
JP2004536034A (en) * 2001-01-08 2004-12-02 ネオルクス コーポレイション Therapeutic and diagnostic compounds, compositions and methods
ITRM20010079A1 (en) 2001-02-16 2002-08-16 Sigma Tau Ind Farmaceuti ADMINODERIVATES OF BIOTIN AND THEM CONJUGATED WITH MACROCYCLIC CHELANTS.
DE10125258A1 (en) * 2001-05-23 2003-01-09 November Ag Molekulare Medizin Method for determining the binding behavior of ligands that specifically bind to target molecules
US6890513B2 (en) 2001-05-25 2005-05-10 Mcmaster University Metal-carborane complexes for radioimaging and radiotherapy and methods for their preparation
BR0305258A (en) * 2002-07-01 2004-10-05 Upjohn Co Hcv ns5b polymerase inhibitors
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2977279A (en) * 1955-11-29 1961-03-28 Monsanto Chemicals Copper chelate coordination complexes
US3027391A (en) * 1959-08-28 1962-03-27 Norman A Frigerio Metal phthalocyanines
US4088747A (en) * 1975-02-19 1978-05-09 Australian Atomic Energy Commission Phenolic amino-carboxylic acid radiopharmaceuticals
DE2616984C3 (en) * 1976-04-17 1981-10-29 Behringwerke Ag, 3550 Marburg Method for the isolation and purification of a placenta-specific glycoprotein
JPS5486602A (en) * 1977-10-27 1979-07-10 Hoffmann La Roche Production of purified alpha 1 phetoprotein
US4293537A (en) * 1978-09-05 1981-10-06 Wong Dennis W Novel chemical method of labeling proteins with 99m Tc-Technetium at physiological condition
JPS567725A (en) * 1979-06-28 1981-01-27 Daiichi Rajio Isotope Kenkyusho:Kk Tumor scanning agent
US4421735A (en) * 1980-04-17 1983-12-20 The Massachusetts General Hospital Radiolabeled diagnostic compositions and method for making the same
US4385046A (en) * 1980-12-15 1983-05-24 Minnesota Mining And Manufacturing Company Diagnostic radio-labeled polysaccharide derivatives
US4957939A (en) * 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US5648063A (en) * 1981-07-24 1997-07-15 Schering Aktiengesellschaft Sterile composition comprising a chelate complex for magnetic resonance imaging
US4452774A (en) * 1982-04-30 1984-06-05 President And Fellows Of Harvard College Isonitrile radionuclide complexes for labelling and imaging agents
DE3228503A1 (en) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg NEW PROTEIN (PP (DOWN ARROW) 1 (DOWN ARROW) (DOWN ARROW) 7 (DOWN ARROW)), METHOD FOR ITS ENHANCEMENT AND PRODUCTION AND USE
US4758682A (en) * 1983-03-17 1988-07-19 California Institute Of Technology Homogeneous coordination compounds as oxidation catalysts
DE3315000A1 (en) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg TISSUE PROTEIN PP (DOWN ARROW) 4 (DOWN ARROW), METHOD FOR ITS RECOVERY AND USE
US4515767A (en) * 1983-06-20 1985-05-07 The Dow Chemical Company Radioactive metals complexed with phosphonate derivatives of dicyclopentadienebis(methylamine)
US4673562A (en) * 1983-08-19 1987-06-16 The Children's Medical Center Corporation Bisamide bisthiol compounds useful for making technetium radiodiagnostic renal agents
US4560548A (en) * 1984-04-10 1985-12-24 The Dow Chemical Company Bone seeking Tc-99m complexes of phosphonate derivatives of bis(aminoalkyl)piperazine
EP0163294A2 (en) * 1984-06-01 1985-12-04 E.I. Du Pont De Nemours And Company Soluble copper salt containing composition useful for forming technetium labelled radiodiagnostic agents
US5066478A (en) * 1984-06-04 1991-11-19 The Dow Chemical Company Radio labeled organic amine phosphonic acid complexes for the treatment of calcific tumors
US5064633A (en) * 1984-06-04 1991-11-12 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes, their formulations and use
US4898724A (en) * 1984-06-04 1990-02-06 The Dow Chemical Company Organis amine phosphonic acid complexes for the treatment of calcific tumors
US5059412A (en) * 1984-06-04 1991-10-22 The Dow Chemical Company Macrocyclic aminophosphonic acid complexes for the treatment of calcific tumors
US4963682A (en) * 1984-07-19 1990-10-16 University Of Florida Novel radiopharmaceuticals and chelating agents useful in their preparation
US4963688A (en) * 1984-07-19 1990-10-16 University Of Florida Compounds for site-enhanced delivery of radionuclides and uses thereof
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
GB8426845D0 (en) * 1984-10-24 1984-11-28 Amersham Int Plc Complexes of technetium-99m
US5019497A (en) * 1984-11-09 1991-05-28 Lennart Olsson Human squamous lung carcinoma cell specific antigens and antibodies
US5242679A (en) * 1985-01-14 1993-09-07 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5175343A (en) * 1985-01-14 1992-12-29 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5120526A (en) * 1985-01-14 1992-06-09 Neorx Corporation Method of producing metal radionuclide labeled proteins for diagnosis and therapy
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
EP0194843B1 (en) * 1985-03-11 1993-01-13 AMERSHAM INTERNATIONAL plc Complexes of technetium-99m with propylene amine oximes
US4746505A (en) * 1985-04-26 1988-05-24 President And Fellows Of Harvard College Technetium radiodiagnostic fatty acids derived from bisamide bisthiol ligands
ZA863205B (en) * 1985-05-01 1987-08-26 Univ New York State Res Found Diagnostic radiopharmaceutical compounds
US5225181A (en) * 1985-06-07 1993-07-06 The Research Foundation Of State University Of New York Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi
US4831122A (en) * 1986-01-09 1989-05-16 Regents Of The University Of Minnesota Radioimmunotoxins
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US4732974A (en) * 1986-03-05 1988-03-22 Mallinckrodt, Inc. Metal ion labeling of carrier molecules
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
US4861869A (en) * 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4859431A (en) 1986-11-10 1989-08-22 The Curators Of The University Of Missouri Rhenium generator system and its preparation and use
EP0273452B1 (en) * 1986-12-30 1994-03-23 Nihon Medi-Physics Co., Ltd. High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilisation
US5279811A (en) * 1987-02-18 1994-01-18 The Du Pont Merck Pharmaceutical Company Ester-substituted diaminedithiols and radiolabeled complexes thereof
US5091514A (en) * 1987-03-26 1992-02-25 Neorx Corporation Metal-radionuclide-labeled proteins and glycoproteins for diagnosis and therapy
AR246956A1 (en) * 1987-05-08 1994-10-31 Salutar Inc Dipyridoxyl phosphate nuclear magnetic resonance imagery contrast agents
US4853209A (en) * 1987-05-18 1989-08-01 The Dow Chemical Company Bone marrow suppressing agents
AU1966188A (en) * 1987-08-07 1989-03-09 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
DE3880974T2 (en) * 1987-11-19 1993-08-26 Univ Vanderbilt RADIOJODIC-CONTAINING BENZAMID AND METHOD FOR USE THEREOF AS RADIO-FORMING AGENTS.
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
EP0329184A3 (en) * 1988-02-19 1990-05-23 Neorx Corporation Antimers and antimeric conjugation
US5112954A (en) * 1988-02-26 1992-05-12 Neorx Corporation Method of enhancing the effect of cytotoxic agents
US5061641A (en) * 1988-04-01 1991-10-29 Immunomedics, Inc. Method for radiolabeling proteins
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US5075099A (en) * 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
CA1340527C (en) * 1988-05-31 1999-05-04 Lidia Vallarino Macrocyclic complexes of yttrium, the lanthanides and the actinides having peripheral coupling functionalities
US5089249A (en) * 1988-06-10 1992-02-18 Neorx Corporation Conjugates for bone imaging and bone cancer therapy
US5002754A (en) * 1988-06-15 1991-03-26 University Of Cincinnati Technetium (III/II) imaging agents
US5071965A (en) * 1988-07-19 1991-12-10 Mallinckrodt Medical, Inc. Novel tc-99m complexes
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5252713A (en) * 1988-09-23 1993-10-12 Neorx Corporation Polymeric carriers for non-covalent drug conjugation
US4987227A (en) * 1988-10-21 1991-01-22 The Research Foundation Of State University Of New York Polyazamacrocycles and their metal complexes
US4925650A (en) * 1988-11-16 1990-05-15 Mallinckrodt, Inc. Technetium -99m complex for examining the renal function
US4976950A (en) * 1988-12-19 1990-12-11 The Dow Chemical Company Bone marrow suppressing agents
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
US4959304A (en) * 1989-05-22 1990-09-25 United States Of America As Represented By The Secretary Of The Navy Production of monoclonal antibodies to treponema denticola by hybridoma TDIII, IIIBB2
US5250666A (en) * 1989-06-16 1993-10-05 Neorx Corporation Radionuclide metal chelates for the radiolabeling of proteins
US5164176A (en) * 1989-06-16 1992-11-17 Neorx Corporation Radionuclide metal chelates for the radiolabeling of proteins
US5021571A (en) * 1989-06-29 1991-06-04 Associated Universities, Inc. Cyclohexyl EDTA monoanhydride
US5334729A (en) * 1989-06-29 1994-08-02 Associated Universities, Inc. Stable radiometal antibody immunoconjugates
DE3930674A1 (en) * 1989-09-11 1991-03-21 Diagnostikforschung Inst BIFUNCTIONAL CHELATE FORMERS FOR COMPLEXING TC AND RE-ISOTOPES, METHOD FOR THE PRODUCTION AND DISPLAY OF CONJUGATES THEREOF AND THEIR USE IN DIAGNOSTICS AND THERAPY
US5053186A (en) 1989-10-02 1991-10-01 Neorx Corporation Soluble irradiation targets and methods for the production of radiorhenium
ATE101596T1 (en) * 1989-12-12 1994-03-15 Amersham Int Plc PHENYLDIAMINODITHIOL DERIVATIVES.
US5080884A (en) * 1989-12-12 1992-01-14 Medi-Physics, Inc. Hydrocarbylphenyl diaminodithiol radionuclide complexes and their use in imaging
US5026913A (en) * 1989-12-12 1991-06-25 Medi-Physics, Inc. Hydrocarbylphenyl diaminodithiol derivatives
US5112953A (en) * 1989-12-29 1992-05-12 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5175257A (en) * 1989-12-29 1992-12-29 Neorx Corporation Radiolabeled proteins for diagnostic or therapeutic use
US5079346A (en) * 1990-05-01 1992-01-07 Trustees Of The University Of Pennsylvania Gallium-labelled imaging agents
US5286848A (en) * 1990-05-07 1994-02-15 Hamamatsu Photonics K.K. Lanthanide cryptate of trisphenanthroline
ES2246502T3 (en) * 1990-08-29 2006-02-16 Genpharm International, Inc. TRANSGENIC NON-HUMAN ANIMALS ABLE TO PRODUCE HETEROLOGICAL ANTIBODIES.
US5382654A (en) * 1992-02-05 1995-01-17 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
US5104638A (en) * 1990-10-29 1992-04-14 Mallinckrodt Medical, Inc. Method of making a radiopharmaceutical complex from a kit
US5116598A (en) * 1990-10-29 1992-05-26 Mallinckrodt Medical, Inc. N4 technetium-99 m complexes for use as radiopharmaceuticals
US5243073A (en) * 1990-12-14 1993-09-07 Mallinckrodt Medical, Inc. Hexadentate ligands useful in radiographic imaging agents
US5112595A (en) * 1990-12-21 1992-05-12 Mallinckrodt Medical, Inc. 99MTC(III) myocardial imaging agents and method of use
US5112594A (en) * 1991-04-04 1992-05-12 Mallinckrodt Medical, Inc. Kit for preparing a technetium-99m myocardial imaging agent
US5133956A (en) * 1991-05-30 1992-07-28 The Dow Chemical Company Radiolabeled metal-binding protein for the treatment of arthritis
IT1248361B (en) 1991-06-28 1995-01-05 Enea PLASMIDIC VECTORS FOR THE EXPRESSION OF GENES IN PLANTS
US5330737A (en) * 1991-12-06 1994-07-19 Mallinckrodt Medical, Inc. Nitrogen-sulfur ligands as opiate receptor drug mimics
US5220000A (en) * 1992-01-23 1993-06-15 Spyros Theodoropulos Bifunctional-bis-quinolinols, and their metal chelates
JPH08504166A (en) * 1992-02-05 1996-05-07 マリンクロッド・メディカル・インコーポレイテッド Radiolabeled peptide compound
US5371184A (en) * 1992-02-05 1994-12-06 Mallinckrodt Medical, Inc. Radiolabelled peptide compounds
US5310536A (en) * 1992-02-06 1994-05-10 Mallinckrodt Medical, Inc. Ligands for improving metal chelate formation kinetics
US5324502A (en) * 1992-04-02 1994-06-28 Purdue Research Foundation Radiopharmaceuticals for imaging the heart
ES2108269T5 (en) * 1992-07-03 2001-09-01 Welfide Corp NEW COMPLAINANT AGENT, COMPLEX COMPOSITE CONSTITUTED BY SUCH AGENT AND A METAL ATOM, AND DIAGNOSTIC AGENT CONTAINING SUCH COMPOUND.
US5319143A (en) * 1992-07-31 1994-06-07 Polaroid Corporation Bis(aminoethanethiols)
NZ252554A (en) * 1993-05-06 1998-01-26 Dow Chemical Co Bicyclopolyazamacrocyclophosphonic acid compounds, complexes, conjugates, as contrast imaging agents
US5968477A (en) * 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
ZA952485B (en) * 1994-03-28 1995-12-15 Nycomed Imaging As Liposomes
US5476644A (en) * 1994-04-13 1995-12-19 Sterling Winthrop Inc. Cyclic triamine chelating agents
EP0759913B1 (en) * 1994-05-19 2000-03-01 Neorx Corporation Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
CA2190727C (en) * 1994-05-19 2006-07-18 Sudhakar Kasina Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
US5508458A (en) * 1995-05-26 1996-04-16 Hoechst Celanese Corporation Chiral catalysts and processes for preparing the same
JP3356289B2 (en) * 1995-06-26 2002-12-16 コンキャット リミティド Compounds with chelating affinity and selectivity for first transition elements and their medical and diagnostic uses
US6005083A (en) * 1997-03-28 1999-12-21 Neorx Corporation Bridged aromatic substituted amine ligands with donor atoms

Also Published As

Publication number Publication date
WO1998043678B1 (en) 1999-04-01
US6177551B1 (en) 2001-01-23
WO1998043678A2 (en) 1998-10-08
DE69837038T2 (en) 2007-07-12
US20030158393A1 (en) 2003-08-21
US7268220B2 (en) 2007-09-11
US6936700B2 (en) 2005-08-30
US6187910B1 (en) 2001-02-13
CA2284653A1 (en) 1998-10-08
US6528627B1 (en) 2003-03-04
EP0971748B1 (en) 2007-02-07
WO1998043678A3 (en) 1999-03-04
EP1813607A3 (en) 2007-08-15
ES2281927T3 (en) 2007-10-01
US20050276754A1 (en) 2005-12-15
JP2002500629A (en) 2002-01-08
US7674886B2 (en) 2010-03-09
DE69837038D1 (en) 2007-03-22
US6005083A (en) 1999-12-21
US20080227961A1 (en) 2008-09-18
EP0971748A2 (en) 2000-01-19
EP1813607A2 (en) 2007-08-01

Similar Documents

Publication Publication Date Title
CA2284653C (en) Tetraaza- or n2s2- complexants, and their use in radiodiagnostics or radiotherapy
JP2021513979A (en) Chemical conjugates of Evans blue derivatives and their use as radiation therapy and contrast agents to target prostate cancer
IE902965A1 (en) Chelating agents for forming complexes with radioactive¹isotopes, metal complexes thereof and use thereof in¹diagnosis and therapy
US9061078B2 (en) Tetraaza macrocyclic compound, preparation method thereof and use thereof
KR20050005425A (en) Tumor imaging compounds
WO2011100829A1 (en) Bifunctional chelating agents
HUT73665A (en) Bifunctional-chelating agents braked with calcogene atoms, pharmaceutical compositions containing them , and use of these compositions in radio- diagnosis and radiotherapy
JPH08504166A (en) Radiolabeled peptide compound
JP2001114792A (en) Bisphosphonic acid derivative and its radioactive isotope- labeled product
US20040167330A1 (en) Novel chelating agents and conjugates thereof, their synthesis and use as diagnois and therapeutic agents
IE920761A1 (en) Chelates, their metal complexes as well as their use in¹diagnosis and treatment
CA2062483A1 (en) Chelates, their metal complexes as well as their use in diagnosis and treatment
US5175256A (en) Protein labeling reagents
US6024937A (en) Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
EP0759913B1 (en) Aromatic amine substituted bridged nitrogen and sulfur donor atom ligands for imaging
CA2031528C (en) Radionuclide metal chelates for the radiolabeling of proteins
US5656253A (en) Ligands useful in radiographic imaging
WO2024037635A1 (en) A trifunctional compound and use thereof
US7780947B2 (en) Tame based chelators and uses thereof
KR0153501B1 (en) Complexes possessing ortho ligating functionality
CA2319694A1 (en) Compound

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20130326